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ABSTRACT 
 
OBJECTIVES 
The study objectives were to evaluate psychometric properties of the EuroQoL–five–dimensional 
questionnaire (EQ–5D–3L) among caregivers of individuals with multiple sclerosis (MS), assess 
caregiver utilities and determine predictors of utilities, and compare caregiver utilities obtained 
from the EQ–5D–3L and the SF–6D.  
METHODS 
A web–based survey was administered to MS caregivers via Qualtrics survey software using 
assistance from a MS patient registry– North American Research Committee on MS 
(NARCOMS).  Measurement properties including convergent, discriminant, and known–groups 
validity, reliability, and ceiling and floors effects of the EQ–5D–3L were tested.  Caregiver 
health utilities were estimated using the EQ–5D–3L and compared with population norms; and 
predictors of utilities were identified using path analyses, a form of structural equational 
modelling (SEM).  Correlational analysis was conducted to assess domain–level agreement of 
EQ–5D–3L and SF–6D utilities.  Scale level agreement was assessed by intra–class correlation 
coefficient (ICC), and Bland–Altman plot.  Multivariable linear regression was used to identify 
determinants of discordance between EQ–5D–3L and SF–6D utilities. 
RESULTS  
The study sample comprised of 215 MS caregivers.  The EQ–5D–3L demonstrated acceptable 
convergent, discriminant, and known–groups validity and reliability.  Ceiling effects were 
present and floor effects were non–existent.  Utilities among MS caregivers (aged 18–44 years) 
were lower than population norms (0.83 vs. 0.91).  Caregiver burden (objective and subjective), 
care recipient disability status, and avoidance and critical coping influenced caregiver utilities.  
The mean utilities were 0.83 and 0.74 for EQ–5D–3L and SF–6D, respectively.  Discernable 
differences between utility distributions were observed.  The measures appeared to agree at the 
domain–level; however, a scale–level agreement was lacking.  Mean discordance of 0.09 was 
noted, and care recipient disability, family income, and caregiver marital status significantly 
predicted discordance between EQ–5D–3L and SF–6D. 
CONCLUSIONS 
The study findings revealed acceptable psychometric profile of the EQ–5D–3L among MS 
caregivers.  Lower utilities among MS caregivers point towards the detrimental impact of 
caregiving.  Factors affecting caregiver utilities identified in this study can be utilized to inform 
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the design of intervention programs/support services for MS caregivers.  Discordance between 
EQ–5D–3L and SF–6D utilities suggest that these estimates may not be interchangeably used to 
calculate quality–adjusted life year (QALY) estimates for resource allocation decisions 
pertaining to MS treatments. 
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MULTIPLE SCLEROSIS 
 
Overview of multiple sclerosis 
 
Multiple sclerosis (MS) is a chronic debilitating disorder that affects the central nervous system 
(CNS) (Grima et al., 2000; Mohr & Cox, 2001).  MS is characterized by attacks of worsening 
neurological function (relapses) interspersed with periods of recovery or no disease activity 
(remission) (National Multiple Sclerosis Society [NMSS], n.d.).  The four types of MS that 
individuals with MS typically experience include relapsing–remitting MS (RRMS), primary–
progressive MS (PPMS), secondary–progressive MS (SPMS), and progressive–relapsing MS 
(PRMS).  MS can result in a range of physical, psychosocial, and social manifestations 
depending on the duration, type and extent of the disease (Forbes, While, Mathes, & Griffiths, 
2006). 
Etiology of multiple sclerosis  
 
Although the etiology of MS is still unknown, it is believed to be due to a combination of 
immunologic, environmental, and genetic factors (National Multiple Sclerosis Society (NMSS), 
n.d.).  Majority of individuals with MS experience their first symptoms between 20 and 40 years 
of age (National Institutes of Health–Multiple Sclerosis Fact Sheet, 2010).  MS is more prevalent 
among Caucasians as compared to African Americans (Cree et al., 2004) and occurs at least 
twice as often among females as compared to males (NIH–MS Fact Sheet, 2010).   
Prevalence of multiple sclerosis 
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More than 2.5 million individuals are affected with MS globally, with roughly 400,000 
individuals affected in the US (NMSS, n.d.).  The three year age–adjusted estimates for 
prevalence in 3 US communities in the southern, middle, and northern US were 47.2, 86.3, and 
109.5 per 100,000 individuals, respectively (Noonan et al., 2010).  A recent study reported an 
estimated annual prevalence of ~572,000 individuals with MS using the Medical Expenditure 
Panel Survey data (Campbell et al., 2014). 
Healthcare utilization and costs of multiple sclerosis 
 
MS is ranked the second most expensive chronic disease after congestive heart failure (Adelman 
et al., 2013).  It typically strikes during young adulthood, which comprises of the most 
economically productive years of life (Weinshenker, 1994).  The progressive and unpredictable 
nature of MS significantly contributes towards the financial burden of MS by limiting patients’ 
ability to work (Naci, et al., 2010b).  Individuals with MS are found to incur higher health care 
resource use compared to healthy individuals (Asche et al., 2010).  In addition, the treatment 
costs associated with MS are known to escalate with increase in the level of disease 
severity/disability of MS patients (Patwardhan et al., 2005).  The early age of onset of MS 
coupled with negligible change in life expectancy leads to long–term treatment of MS, thereby 
resulting in considerable healthcare spending (Owens et al., 2013).  The average lifetime cost to 
treat one patient with MS was estimated as $2.5 million (1994 dollars).  The total economic 
burden of MS in the US accounted for $6.8 to $11.9 billion, with one–fifth of the total costs 
attributed to informal care (Whetten–Goldstein, Sloan, Goldstein, & Kulas, 1998).  The 
economic burden of MS is largely driven by direct non–medical costs including those of assistive 
devices, aids, formal and informal care, and indirect costs associated with loss in productivity 
(Naci et al., 2010b).  As per a recent published review pertaining to financial burden of MS, the 
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total annual per patient all–cause costs for MS were estimated between $8,528 and $54,244 
(Adelman et al., 2013).   
Treatment of multiple sclerosis 
 
Given that MS is an incurable condition, the treatment goal lies in symptom management by 
means of reducing the relapse frequency and delaying the disease progression.  Management of 
MS includes treatment with non–pharmacological and pharmacological therapy.  Non–
pharmacological treatments of MS include physical therapy, occupational therapy, rehabilitation, 
and complementary and alternative medicine (CAM).  Pharmacological treatment of MS 
includes Food and Drug Administration (FDA) approved beta–interferons and disease modifying 
therapy (DMT) indicated to reduce disease activity and progression among individuals with 
progressive forms of MS (Cross & Naismith, 2014; NMSS, n.d.).   
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HEALTH–RELATED QUALITY OF LIFE 
There is a growing interest in health-related quality of life (HRQOL) measurement to inform 
healthcare resource allocation decisions.  Assessment of HRQOL has gained acceptance due to 
its ability to include both positively and negatively valued aspects of life.  Patients are less likely 
to comprehend physiological measures and have little interest in these measures.  Also, patients 
with same clinical parameters do not have similar responses to HRQOL measures (Guyatt, et al., 
1993).  Considering the relevance of HRQOL end–points among patients and its utility in 
informing resource allocation decisions there is a widespread scope of employing these 
measures.  In addition, it has been reported that HRQOL has become a conventional end–point in 
clinical trials pertaining to MS treatments (Solari, 2012).   
Types of HRQOL measures 
 
The three types of measures used to assess HRQOL include generic health indices and profiles, 
specific measures, and health state preference/utility/value–based measures (Bennett & Torrance, 
1996).  Generic instruments such as single indicators, health profiles, and utility measures 
provide a summary measure of HRQOL.  Specific HRQOL measures assess issues relevant to a 
particular disease state, population, or area of function (Guyatt et al., 1993).  Particularly, health 
state preference/utility/value–based measures incorporate both positive and negative aspects of a 
health state, summarizing an individual’s overall assessment of quality of life for a health state 
into a single index (Fisk et al., 2005; Prosser, Kuntz, Bar–Or, & Weinstein, 2003; Tsevat, 2000). 
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HRQOL among individuals with MS 
The negative impact of MS on health–related quality of life (HRQOL) among patients is well–
documented in the literature (Benito‐León et al., 2003).  Individuals with MS experience a wide 
range of cognitive, physical, and psychosocial symptoms that adversely influence their HRQOL 
(Benito–León, Morales, & Rivera‐Navarro, 2002; Benito–León, Morales, Rivera–Navarro, & 
Mitchell, 2003; Jones, Pohar, Warren, Turpin, & Warren, 2008).  When compared to those with 
other chronic diseases such as rheumatoid arthritis, epilepsy, diabetes, and inflammatory bowel 
disease, individuals with MS are found to score low on HRQoL (Hermann et al., 1996; Rudick et 
al., 1992).   
HRQOL among caregivers of individuals with MS 
 
Mobility impairment is one of the most disabling effects of MS that restricts the ability of 
affected individuals to perform routine activities, resulting in dependence on friends and family 
(Aronson et al., 1996).  MS not only imposes a considerable burden on individuals with MS but 
also on their family/friends (informal caregivers) and the society (Aronson, 1997; Fisk et al., 
2005; Jones et al., 2008).  Analogous to other neurological diseases, caring for individuals with 
MS is burdensome and adversely impacts caregiver health (Pakenham, 2005).  Neuropsychiatric 
symptoms of MS are also known to significantly contribute toward caregiver distress (Figved et 
al., 2007).  Caregivers of individuals with MS are reported to incur higher anxiety and stress 
compared to non–caregiver controls, and have lower quality of life compared to the general 
population (Alshubaili et al., 2008; Janssens et al., 2003).  Due to the dependence of individuals 
with MS on their caregivers, a combined patient and caregiver approach, as opposed to a patient–
focused approach for treatment of MS has been suggested (Benito–León et al., 2011).  The 
burden imposed by MS on both patients and caregivers necessitates incorporation of “spillover 
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effects” in economic evaluation of MS treatments/interventions designed to alleviate the 
symptoms of a disease.  The term “spillover effects” has been associated with both paid and 
informal caregivers, family members and sometimes friends who care for diseased individual 
(Wittenberg & Prosser, 2013).   
The US Public Health Service panel on cost–effectiveness (CE) in health and medicine 
recommended the use of generic health state preference/value systems such as Health Utility 
Index (HUI) and EuroQoL–five–dimensional questionnaire (EQ–5D–3L) to describe outcomes 
(quality adjusted life years [QALY]) for cost–utility analyses (CUA) (Gold et al., 1996).  It is 
suggested that incorporation of health utility of family members/caregivers in the economic 
evaluation (CUA) may reflect the true effectiveness of the treatment/intervention (Wittenberg & 
Prosser, 2013). 
Several studies have estimated health utility among individuals with MS (Fogarty et al., 
2013; Gottberg et al., 2006; Grima et al., 2000; Hemmett et al., 2004; Naci et al., 2010a); 
however, limited information currently exists about health utility among caregivers of 
individuals with MS.  Argyriou et al. (2011) found lower mean EuroQoL Visual analogue scale 
(EQ–5D–3L VAS) score among a small sample of primary caregivers of individuals with MS in 
Greece as compared to controls (Argyriou et al., 2011).  In their study examining the burden and 
health utility among caregivers of individuals with MS using data from the National Health and 
Wellness Survey (NHWS), Gupta et al. (2012) found the higher caregiver burden and lower 
health utility among MS caregivers compared to non–caregiver controls.  Although Gupta and 
colleagues meaningfully contributed to the MS caregiver literature, a few limitations in their 
study can be noted.  These limitations include lack of data pertaining to duration of MS 
diagnosis, course of MS, disability status and care recipient’s relationship with the caregiver 
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(Gupta et al., 2012).  In addition, use of a pre–existing survey dataset precluded information on 
duration of caregiving, coping strategies employed, and social support perceived by caregivers of 
individuals with MS.  The role of caregiver resources on health state preferences/utility of MS 
caregivers has not been examined.  In order to completely understand the burden imposed by MS 
on caregivers, information pertaining to caregiver resources is critical.   
Recently, Acaster et al. (2013) examined health utility among unpaid caregivers of 
individuals with MS in the United Kingdom (UK).  A preference–based health utility measure 
was used to determine the preferences of caregivers of individuals with MS.  Caregivers of 
individuals with MS reported significantly lower HRQOL as compared to matched controls in 
the general UK population.  Additionally, lower HRQOL was reported among caregivers of MS 
patients with greater mobility problems assessed using the Patient–Determined Disease Steps 
(PDDS) instrument.  Although the findings of the study conducted by Acaster and colleagues 
generated substantial evidence regarding the adverse influence of caring for an individual with 
MS on health state preferences among caregivers, generalizability to the US population is 
questionable.  Moreover, similar to that in the study by Gupta and colleagues, Acaster et al. 
(2013) also failed to examine the role of caregiver resources such as coping and social support on 
health utility and burden experienced by MS caregivers.  Given the dearth of information 
pertaining to factors affecting health utility and burden experienced by caregivers of individuals 
with MS, more research is needed in this area.  
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STUDY NEED 
I. Need for assessment of psychometric properties of a health utility instrument among 
caregivers of individuals with MS. 
A review of the literature revealed a considerable gap in the research examining health utility of 
caregivers of individuals with MS, yielding a few studies in this area.  Gupta et al. (2012) 
assessed health utility of caregivers of individuals with MS using the short form–6–dimensional 
measure (SF–6D) that was derived from the 12–item Medical Outcomes Study Short Form 
Health Survey version 2 (SF–12v2) questionnaire.  In a recent study, Acaster et al. (2013) 
examined health utility among unpaid caregivers of individuals with MS in the UK using the 
EQ–5D–3L questionnaire.  In another study, quality of life among primary caregivers of 
individuals with MS was assessed using the Greek–validated version of the EQ–5D–3L 
(Argyriou et al., 2011).  Generic instruments such as the SF–6D and the EQ–5D–3L are designed 
for use across populations.  Evidence for broad application of these instruments can be obtained 
by assessment of their psychometric properties in different populations.  Currently, no evidence 
exists about the psychometric properties of these instruments among caregivers of individuals 
with MS.   
Chapter 2 seeks to address the aforementioned research gap by evaluating the 
psychometric properties of the EQ–5D–3L in the MS caregiver population.  The EQ–5D–3L is 
generic measure of HRQOL that is designed to be used in different populations.  Convergent, 
discriminant, and known groups validity were evaluated.  In addition, reliability, ceiling and 
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floor effects were assessed.  Evidence regarding acceptable psychometric properties is likely to 
promote future use of the health utility instrument to assess health status of MS caregivers and 
generate confidence in the use of health utility values in economic evaluations of MS 
treatments/interventions. 
II. Need to examine health utility and its determinants among caregivers of individuals with 
MS.  
Previous research has demonstrated that caregivers of individuals with a chronic disease such as 
MS score low on HRQOL (Benito‐León et al., 2003).  Given the relevance of incorporating 
“spillover effects” in economic evaluation of MS treatments/interventions, and dearth of 
information pertaining to factors affecting health utilities among MS caregivers, more research is 
needed.   
Chapter 3 expands the current understanding of health utility among caregivers of individuals 
with MS using an adaptation of the theoretical model developed by Yates and colleagues (1999).  
Data relevant to factors influencing health utility (e.g. care recipient’s disability status, caregiver 
objective and subjective burden, social support, and coping) among caregivers of individuals 
with MS was obtained using survey methodology.  The interrelationships among factors 
affecting health utility of MS caregivers were also examined using a non–traditional analytical 
technique known as path analysis, a structural equation modeling (SEM) approach. 
III. Need to compare health utility scores and ascertain the level of agreement between utility 
scores from two health utility measures. 
Health utility estimates obtained from different multi–attribute health utility measures are found 
to vary across diseases and populations (Grieve et al., 2009).  Differences in health utility 
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estimates are likely to result in differential QALYs estimates that may impact results of CUA 
(Ferreira et al., 2008).  Health utility scores obtained from the EQ–5D–3L and the SF–6D were 
compared and the level of agreement (domain– and scale–level) between the scores was 
ascertained.  In addition, an exploratory analysis to determine predictors of discordance of 
estimates from the two measures was carried out. 
Chapter 4 expands the current understanding of differences and agreement between the 
EQ–5D–3L and SF–6D in the MS caregiver population. 
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SPECIFIC AIMS AND OBJECTIVES 
1. To examine psychometric properties of the EQ–5D–3L among caregivers (primary support 
providers) of individuals with MS. 
2. To measure health utility scores among caregivers of individuals with MS using the EQ–5D–
3L.  
3. To determine the factors (care recipient MS severity [assessed using Caregiver Determined 
Disease Steps], caregiver burden [assessed using Montgomery Burden Scale], social support 
[assessed using Multidimensional Scale of Perceived Social Support], caregiver coping 
strategy [assessed using Coping with Multiple Sclerosis Caregiving Inventory]), affecting 
health utility in caregivers of individuals with MS. 
4. To compare estimates obtained from the EQ–5D–3L and the SF–6D and investigate the level 
of agreement between the health utility scores obtained from the two measures. 
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2 CHAPTER 2 
PSYCHOMETRIC PROFILE OF THE EUROQOL FIVE–DIMENSIONAL 
QUESTIONNAIRE (EQ–5D–3L) AMONG CAREGIVERS OF INDIVIDUALS WITH 
MULTIPLE SCLEROSIS (MS) 
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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic debilitating disease affecting the central nervous system 
(Mohr & Cox, 2001).  It is characterized by impaired transmission of nerve impulses (Grima et 
al., 2000) that manifest into a wide range of symptoms including fatigue, numbness, walking 
disabilities, and pain among others (NMSS).  MS affects ~572,000 individuals in the United 
States (US) (Campbell et al., 2014) and occurs at least twice as often among women compared to 
men (NMSS).  The total annual all–cause healthcare costs of MS is estimated to be as high as 
$54,244 per patient.  Over one–fifth of these costs are attributed to indirect costs of disability, 
absence from work, and underemployment. (Adelman et al., 2013).   
The early age of onset of MS and mobility impairment among individuals with MS not 
only restricts their functional independence but also their quality of life (Dunn 2010).  As a 
result, individuals with MS depend on their family (henceforth referred to as ‘caregivers’) for 
assistance with a range of day–to–day activities (Gupta et al., 2012).  The unpredictability in the 
disease course of MS and the associated functional deficits bring about challenges for caregivers 
involved in the care process of those with MS.  In addition, there is evidence to suggest that 
caregivers of individuals with MS experience significant burden (Bayen et al., 2015; Buhse 
2008) and impaired health–related quality of life (HRQOL) (Patti et al., 2007; Arnett 2007; 
Aymerich et al., 2009; Benito‐León et al., 2003; Gupta et al., 2012; Patti et al., 2007).  Buchanan 
and Huang (2011) reported lower mental HRQOL among caregivers of individuals with MS in 
the US.  Family income and caregiver age were reported as significant predictors of caregiver 
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HRQOL.  In addition, an inverse relationship between caregiver burden and HRQOL was 
reported.  Other researchers have also examined HRQOL among MS caregivers (Aymerich et al., 
2009; Gupta et al., 2012; Patti et al., 2007).  The results from these studies highlight the 
significant negative health impact of caring for an individual with MS on caregivers.   
Though HRQOL of MS caregivers has been well studied, the health state preferences for 
this population are not well understood.  Health state preference refers to an individual’s overall 
desirability for the health state summarized into a single numerical index between 0 and 1, where 
0 and 1 correspond to the worst and best possible health state, respectively.  Health state 
preference is a broad umbrella term that encompasses both values and utilities, where values are 
preferences generated under certainty by means of time trade–off (TTO) elicitation technique; 
whereas, utilities are generated under uncertainty using standard–gamble (SG) technique.  The 
terms– preferences, values, and utilities have been interchangeably used in the literature.  Health 
state preferences/utilities are used in economic evaluations of treatments/interventions to support 
resource allocation decisions (Neumann et al., 2000).  The impact of a treatment/intervention on 
health utilities and duration of life is incorporated into quality adjusted life years (QALY), a 
summary health outcome measure employed in economic evaluations.   
The US panel on cost–effectiveness in health and medicine recommended incorporating 
utilities of significant others (caregivers) in economic evaluations of health care 
treatments/interventions (Gold et al., 1996).  Al–Janabi et al. (2011) suggested that caregiver 
QALY gains that stem directly from the treatment/intervention as well as indirect gains due to a 
change in the care requirement should be considered when evaluating healthcare 
treatments/interventions.  In addition, Wittenberg and Prosser (2013) noted that failure to 
incorporate caregiver health gains/losses (‘spillover effects’) in health economic evaluations are 
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likely to undermine the true effectiveness of the treatment/intervention under consideration 
(Wittenberg & Prosser, 2013).  Given the considerable involvement of caregivers in the well–
being of individuals with MS and the burden experienced by caregivers, it is important to 
consider caregiver QALYs in economic evaluation of MS treatments/interventions along with 
patient QALYs.   
The use of generic health state preference/value systems such as the EuroQoL–five–
dimensional questionnaire (EQ–5D–3L) has been recommended by the US panel on cost–
effectiveness in health and medicine to calculate QALYs (Gold et al., 1996).  The EQ–5D–3L is 
a generic health state preference measure that comprises of an index system and a visual 
analogue scale (EQ–5D–3L VAS).  The EQ–5D–3L index system captures five domains of 
health, with 3 levels for each domain (1 = ‘no problems’, 2 = ‘some problems’, and 3= ‘extreme 
problems’).  The EQ–5D–3L has been extensively used in clinical trials, observational studies, 
and population health surveys as it imposes minimal cognitive burden on respondents (EuroQoL 
1990; Pickard et al., 2008).  It has been employed in caregiver research examining health utilities 
among caregivers of individuals with neurological disorders including MS, Alzheimer’s disease, 
autism, stroke, Parkinson’s disease (PD), dementia, and psychoses (Acaster et al., 2013; Flyckt et 
al., 2013; Karlawish et al., 2008; Khanna et al., 2013a; Pickard et al., 2004; Serrano–Aguilar et 
al., 2006). 
A few researchers have evaluated psychometric properties of the EQ–5D–3L among 
caregiver populations.  For example, Khanna et al. (2013b) reported evidence for a good 
psychometric profile of the EQ–5D–3L among caregivers of children with autism.  They found 
support for acceptable measurement properties including convergent, discriminant, and known–
groups validity of the EQ–5D–3L (Khanna et al., 2013b).  In another study, Diaz–Redondo et al. 
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(2013) examined psychometric properties of the EQ–5D–3L among caregivers of individuals 
with dementia.  Evidence for satisfactory internal consistency reliability and convergent, 
discriminant validity was noted in their study. 
The EQ–5D–3L has also been used to examine health utilities among MS caregivers.  
Argyriou et al. (2011) utilized the Greek–validated version of the EQ–5D–3L to assess quality of 
life among caregivers of individuals with MS.  They found lower EQ–5D–3L VAS scores among 
MS caregivers compared to controls.  Acaster et al. (2013) reported lower health utilities (EQ–
5D–3L) among MS caregivers as compared to matched controls in the United Kingdom (UK) 
population.  Their study results pointed towards the detrimental impact on caregivers’ HRQOL 
as a result of their care responsibilities and suggested inclusion in economic evaluations of MS 
treatments.  Though the EQ–5D–3L has been used among MS caregivers, its psychometric 
properties in this population are unknown.  The purpose of this study is to examine the validity 
(convergent, discriminant, and known–groups) and reliability (internal consistency) of the EQ–
5D–3L among MS caregivers.  In addition, ceiling and floor effects of the EQ–5D–3L were 
examined. 
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RESEARCH DESIGN AND METHODS 
Study design 
A cross–sectional, non–experimental design was employed in this study.  A self–administered 
web–based survey was administered to a convenience sample of MS caregivers.  
Study sample and data source 
Informal caregivers of adults (≥18 years of age) with MS in the US constituted the target 
population for this study.  A MS patient registry – North American Research Committee on 
Multiple Sclerosis (NARCOMS) was contacted to recruit a convenience sample of informal 
caregivers of individuals with MS.  NARCOMS is a volunteer registry of more than 37,000 MS 
patients that was initiated by the consortium of MS centers (CMSC).  Individuals with MS 
registered with NARCOMS were requested to identify their caregiver (primary support provider) 
or ‘the person most often available to assist or support when needed, regardless of the level and 
frequency of support involved’. 
Sample size 
This study was conducted as part of a larger study aimed at studying health outcomes among MS 
caregivers.  A sample size of 250 was considered appropriate based on the analysis technique 
required to achieve the objectives of the larger parent study. 
Data collection 
A cover letter was mailed to individuals with MS enrolled in NARCOMS.  Individuals with MS 
were requested to identify their caregiver (primary support provider) irrespective of the level and 
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frequency of support received from their caregiver.  Registry participants were also mailed a 
separate survey invitation letter addressed to their caregiver requesting their participation in this 
study.  The survey invitation letter addressed to the caregiver explained about the purpose of the 
study, emphasized voluntary study participation, and included the link to the survey hosted on 
Qualtrics software system (Qualtrics Inc. Provo, UT).  Cover letter and survey invitation letter 
were mailed by NARCOMS to protect the patient identity.  Caregivers who completed the 
survey were emailed a $15 Amazon gift code as an appreciation of their study participation.  An 
approval from the University of Mississippi’s Institutional Review Board (UM–IRB) was 
obtained under exempt status before study initiation.   
Study measures 
 
Although the survey administered to caregivers included several measures required for the 
purpose of the larger study, only those relevant to the current study objectives have been 
described below.   
The EuroQoL–five–dimensional questionnaire (EQ–5D–3L).  The EQ–5D–3L is an indirect 
preference–based measure that includes a five–domain index (EQ–5D–3L index) system and a 
VAS (EQ–5D–3L VAS) (EuroQoL, 1990).  The EQ–5D–3L index system captures five domains 
of health including mobility, self–care, usual activities, pain/discomfort, and anxiety/depression.  
Extent of problems on each domain are assessed on a three–level scale ranging from 1 indicating 
“no problems” to 3 indicating “extreme problems”.  A total of 243 (35) unique health states can 
be assessed using the EQ–5D–3L.  Based on the EQ–5D–3L index system, the best and the worst 
health state are described as ‘11111’ and ‘33333’, respectively.  A scoring algorithm is used to 
convert the responses on the EQ–5D–3L index system into an index score that ranges between –
0.59 and 1.00 (Shaw et al., 2005).  The EQ–5D–3L index scores can be compared with the value 
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set representative of the general US population derived using the time trade–off (TTO) 
preference elicitation technique (EuroQoL, 1990).  The EQ–5D–3L VAS is a vertical 20 cm line 
wherein end–points are marked from 0 = “worst imaginable health state” to 100 = “best 
imaginable health state” (EuroQoL, 1990).   
Medical Outcomes Study Short–Form Health Survey version 2 (SF–12v2). The SF–12v2 is a 
generic health status instrument that includes 12 items (Ware et al., 2002).  SF–12v2 assesses 
eight sub–domains of health including physical functioning (PF), role physical (RP), bodily pain 
(BP), general health (GH), vitality (V), social functioning (SF), role emotional (RE), and mental 
health (MH).  In addition, summary physical health (physical component score [PCS]) and 
mental health (mental component score [MCS]) are also provided.  Scores for the eight sub–
domains and summary scales were determined using the Quality Metric OptumInsight SF Health 
OutcomesTM Scoring Software.  The higher the score, better the health status. 
Montgomery Burden Scale.  Caregiver burden was assessed using the 22–item Montgomery 
burden scale that yields caregiver objective and subjective burden subscales (Montgomery, 
1985).  Objective burden is assessed using nine items that are measured on a five–point scale 
with the rating system: a lot more (better); a little more (better); the same; a little less (worse); a 
lot less (worse).  Subjective caregiver burden is assessed using thirteen items measured on a 
five–point scale with the rating system: rarely/never; a little of the time; sometimes; often; most 
of the time.  Considering that the population of interest for this study included caregivers, minor 
modifications to the scale were made.  The subjective burden subscale was revised as per the 
current study population (i.e. caregivers).  For example, the item ‘I feel that my (relative) makes 
requests which are over and above what s/he needs’ was changed to ‘I feel that the person that I 
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care for makes requests which are over and above what s/he needs’.  The Cronbach’s alpha for 
the revised caregiver subjective burden subscale was found to be 0.70.   
Caregiver–Determined Disease Steps (CDDS).  Patient determined disease steps (PDDS) is a 
measure that is used to assess self–reported functional disability among individuals with MS 
(Hohol et al., 1995; Hohol et al., 1999).  The PDDS is measured using a 1–point scale with 9 
levels of MS–related functional disability, where 0 = “normal”, 1 = “mild disability”, 2 = 
“moderate disability”, 3 = “gait disability”, 4 = “early cane”, 5 = “bilateral support”, 6 = 
“wheelchair”, 7 = “wheelchair/scooter”, and 8 = “bedridden”.  For the purpose of the current 
study, the PDDS was adapted into a caregiver–administered version (caregiver determined 
disease steps [CDDS]).  We modified the wording of description of each category of disability in 
the PDDS to make it suitable for caregivers to provide information about care recipient’s level of 
functional disability.  For example, the description of moderate disability category in the PDDS 
was changed from “I don't have any limitations in my walking ability. However, I do have 
significant problems due to MS that limit daily activities in other ways” to “the care recipient 
does not have any limitations in his/her walking ability. However, the care recipient does have 
significant problems due to MS that limit daily activities in other ways”.  Permission and 
approval for the revised PDDS (CDDS) was obtained from NARCOMS prior to its use in this 
study.  For the CDDS, scores from 0–2 represent ‘no walking disability’, 3–5 represent ‘mild to 
moderate disability’, and 6–8 represent ‘severe to total disability’. 
Socio–demographic characteristics of caregivers and care recipients 
Caregivers’ age, gender, race/ethnicity, education, marital status, income, employment status, 
co–residence with care–recipient, their relationship with the care–recipient, weekly hours of 
assistance provided to care recipients, whether or not they assist the care recipient with 
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injections, and places they took the care recipient for treatment–related injections were obtained.  
Information pertaining to care recipient’s age, gender, race/ethnicity, years since MS diagnosis, 
type of MS, health insurance coverage, prescription medications used in the treatment of MS 
(yes/no), and route of medication administration (oral/injection) were obtained.   
Data analyses 
Study data was analyzed using the Statistical Package for Social Sciences (SPSS) version 22.0 
software (IBM, Corporation, Armonk, NY, US).  Responses were examined for missing data, 
and those with greater than 15% missing data were excluded from analysis.  Case mean 
substitution was employed for responses with fewer than 15% missing data.  Considering that the 
web version of the EQ–5D–3L requires participants to complete all items in order to proceed 
further with the survey, there were no missing data for EQ–5D–3L.   
Means and standard deviations, and frequencies and percentages were calculated for 
continuous and categorical variables, respectively.  For each of the five domains of the EQ–5D–
3L, the proportion of respondents with ‘no problems’, ‘some problems’, and ‘extreme problems’ 
were reported.  The mean EQ–5D–3L index and EQ–5D–3L VAS scores and the five most 
common EQ–5D–3L health states for the sample have also been reported. 
Convergent validity refers to the extent to which similar constructs correlate.  Moderate 
to strong correlation between domains of measures that capture the same underlying construct is 
considered as evidence of convergent validity (Khanna et al., 2013b).  In the context of the 
current study, it reflects the extent to which EQ–5D–3L domains are correlated with theoretically 
similar domains.  To examine convergent validity of the EQ–5D–3L, we studied the correlation 
of the five domains of the EQ–5D–3L with theoretically related constructs from the SF–12v2.  In 
addition, subscales scores on the Montgomery caregiver burden scale (caregiver objective and 
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subjective burden) were compared with EQ–5D–3L index and EQ–5D–3L VAS to determine 
convergent validity of the EQ–5D–3L.  Correlation coefficient between related domains of the 
EQ–5D–3L and SF–12v2, and between subscale scores on Montgomery burden scale and the 
EQ–5D–3L were computed using Spearman’s rank correlation coefficient.  The value of 
correlation coefficient between 0.1 and 0.29 was considered as weak, 0.3–0.49 as moderate, and 
0.5 and above was indicative of strong correlation (Cohen, 1988).  Moderate to strong correlation 
between related constructs was regarded as evidence of acceptable convergent validity.  
Relationship between the following pairs of domains was tested:  EQ–5D–3L mobility domain 
and SF–12v2 PF domain (–), EQ–5D–3L anxiety/depression domain and SF–12v2 MH domain 
(–), EQ–5D–3L anxiety/depression domain and Montgomery burden scale objective burden (+), 
EQ–5D–3L anxiety/depression domain and Montgomery burden scale subjective burden (+), 
EQ–5D–3L pain/discomfort domain and SF–12v2 BP domain (–), EQ–5D–3L usual activities 
domain and SF–12v2 BP domain (–), EQ–5D–3L usual activities domain and SF–12v2 RP 
domain (–), EQ–5D–3L self–care domain and SF–12v2 BP domain (–), EQ–5D–3L self–care 
domain and SF–12v2 RP domain (–), EQ–5D–3L index and SF–12v2 PCS (+), EQ–5D–3L 
index and SF–12v2 MCS (+), EQ–5D–3L index and Montgomery burden scale objective burden 
(–), EQ–5D–3L index and Montgomery burden scale subjective burden (–), EQ–5D–3L–VAS 
and SF–12v2 GH domain (+), EQ–5D–3L VAS and SF–12v2 PCS domain (+), and EQ–5D–3L 
VAS and SF–12v2 MCS domain (+). 
Discriminant validity refers to the extent to which theoretically unrelated constructs 
correlate.  A weak and insignificant correlation between unrelated constructs is considered an 
evidence of discriminant validity (Khanna et al., 2013b).  Discriminant validity was assessed by 
demonstrating a weak and insignificant association between theoretically unrelated domains of 
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the EQ–5D–3L and SF–12v2.  Spearman’s rank correlation coefficient was calculated between 
unrelated constructs to test for discriminant validity of the EQ–5D–3L.  Correlation between the 
following pairs of domains was tested: EQ–5D–3L mobility domain and SF–12v2 RE domain (–
), EQ–5D–3L mobility domain and SF–12v2 MH domain (–) and EQ–5D–3L usual activities 
domain and SF–12v2 RE domain (–). 
Known–groups validity refers to the ability of a measure to differentiate between groups 
of individuals that are inherently different on certain variables.  The sensitivity of the EQ–5D–3L 
to known group differences was evaluated.  Known–groups validity was tested by assessing 
variation in caregiver EQ–5D–3L score across care recipient disability levels assessed using the 
CDDS (‘no walking disability’, ‘mild to moderate disability’, and ‘severe to total disability’).  
Kruskal–Wallis analysis of variance (ANOVA) was used compare EQ–5D–3L index and EQ–
5D–3L VAS scores across care recipient disability levels.  Additionally, because prior studies 
have demonstrated increasing caregiver age to be associated lower HRQOL among MS 
caregivers (Buchanan & Huang, 2011; Patti et al., 2007), we compared EQ–5D–3L index and 
EQ–5D–3L VAS scores across age of caregivers using Spearman’s rank correlation coefficient.   
A measure is considered to exhibit ceiling effect when a significant proportion of 
respondents obtain the best possible score on it.  Similarly, a measure is considered to exhibit 
floor effects when several respondents have the worst/least possible score on the instrument.  
Ceiling and floor effects on responses to the EQ–5D–3L were assessed by determining the 
proportion of respondents with the best (‘11111’) and worst (‘33333’) possible score, 
respectively.  Greater than 15% of the responses with best or worst possible score on the EQ–
5D–3L was indicative of ceiling and/or floor effects, respectively (McHorney & Tarlov, 1995).  
Internal consistency reliability of EQ–5D–3L was calculated using Cronbach’s alpha, with value 
30 
 
0.70 or more considered acceptable (Nunnally, 1970).  Corrected item–total correlation was also 
calculated to assess the reliability for each domain (item) of the EQ–5D–3L.  A value of 0.20 or 
more was considered as an acceptable value of the correlation coefficient for an item with the 
item–deleted total score (Streniner et al., 2014).  
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RESULTS 
A total of the 221 MS caregivers responded to the survey.  Six respondents had 15% or more 
missing data, and were therefore excluded from study analyses.  Thus, the final study sample 
included 215 MS caregivers.  Demographic characteristics of the final sample of MS caregivers 
and care recipients have been summarized in Table 2.1.  A greater proportion of the caregivers 
were male (60.8%), White/Caucasian (87.9%), and had an average age of 56.5 (±13.7) years, 
respectively.  In terms of the relationship with the care recipient, over three fourths (76.3%) of 
the caregivers were either a spouse or significant other of the care recipient with MS.  Greatest 
proportion of the caregivers were married (78.1%) and resided with the care recipient (89.8%).  
A third (33.4%) of the caregivers had an annual family income of $49,000 or less.  On average, 
caregivers were providing care since 15.6 (±9.6) years and 36.3% of the caregivers spent 20 
hours/week or more looking after an individual with MS.   
Greater than three fourths of the care recipients were reported to be female (77.7%) and 
White/Caucasian (93.5%).  The average age for the care recipients was reported as 57.6 (±10.4) 
years.  Roughly a third (34.4%) of the care recipients were reported to be ‘mild to moderate 
disability’, while another third (34.4%) were reported to be severely or totally disabled.  Over 
half (50.5%) of the care recipients were reported to have relapsing–remitting MS, a fifth had 
secondary–progressive MS (20.6%), primary–progressive MS (15.0%), and progressive–
relapsing MS (6. 1%). 
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Table 2.1 Demographic characteristics of multiple sclerosis (MS) caregivers and care recipients 
Characteristic n % 
Caregiver characteristic   
Gender   
  Male 130 60.8 
  Female 84 39.2 
Age, mean (sd) 56.5 13.7 
Race/Ethnicity   
  African American/Black 10 4.7 
  White/Caucasian 189 87.9 
  Other* 16 7.4 
Marital Status   
  Never Married 19 8.8 
  Married 168 78.1 
  †Other 28 13.1 
Education level   
  Less than high school 3 1.4 
  High school or technical school 30 14.0 
  College degree 127  59.1 
  Masters degree 33 15.3 
  Doctoral degree 12 5.6 
  Professional degree 9 4.2 
Employment Status   
  Employed/self–employed full time  102 47.4 
  Employed part–time 18 8.4 
  Other‡ 94 43.8 
Income   
  <$15,000 16 7.4 
  $15,000–$29,999 19 8.8 
  $30,000–$49,999 37 17.2 
  $50,000–$100,000 68 31.6 
  Over $100,000 37 17.2 
  Don’t wish to answer 38 17.7 
Relationship to the care recipient   
  Spouse/Significant other 164 76.3 
  Parent 16 7.4 
  Child 14 6.5 
  Friend/Neighbor 11 5.1 
  Other 8 3.7 
Caregiving assistance (hours/week)   
  ≤5 hours 65 30.2 
  6–10 hours 29 13.5 
  11–15 hours 26 12.1 
  16–20 hours 17 7.9 
  ≥20 hours 78 36.3 
Care years, mean (sd) 15.6 9.6 
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Living with care recipient   
  Yes  193 89.8 
  No 22 10.2 
Assist with injections   
  Yes 38 40.0 
  No 57 60.0 
Injection place of administration   
  Infusion center 25 25.8 
  Hospital 17 17.5 
  Physician office 16 16.5 
Care recipient characteristic   
Age, mean (sd) 57.6  10.4 
Gender    
  Male 48 22.3 
  Female 167 77.7 
Race/Ethnicity   
  African American/Black 7 3.3 
  White/Caucasian 201 93.4 
  Other€ 13 6.1 
Type of MS   
  Relapsing–Remitting 108 50.5 
  Primary–Progressive  32 15.0 
  Secondary–Progressive  44 20.6 
  Progressive–Relapsing  13 6.1 
  Don’t know 17 7.9 
Disability status   
  No walking disability 67 31.2 
  Mild to moderate disability 74 34.4 
  Severe to total disability 74 34.4 
Medication use   
  Yes 164 77.0 
  No 49 23.0 
Medication route of administration   
  Oral 84 51.2 
  Injection 97 59.2 
Health insurance   
  Yes 209 97.2 
  No 6 2.8 
Total 215 100.0 
SD standard deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, Native Hawaiian/Other 
Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with partner 
‡Other includes retired, home–maker, student, seeking work, etc. 
€Other includes Asian/Indian Asian, Hispanic, etc.; N = 215 
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EQ–5D–3L descriptives  
The mean EQ–5D–3L score for the study sample was 0.830 (±0.170) with a median of 0.827 
(interquartile range [IQR] = 0.20).  The mean EQ–5D–3L VAS score was 79.09 (±15.16) with a 
median of 82.0 (IQR = 19).  The five most commonly reported EQ–5D–3L health states and the 
corresponding EQ–5D–3L index and EQ–5D–3L VAS scores have been reported in Table 2.2.  
Almost 31% of the sample rated their health state as ‘11111’ (best possible state) and none 
reported their health state as ‘33333’ (worst possible state).  Caregivers who rated themselves as 
‘11111’ recorded a full health EQ–5D–3L index value (1.00) and a mean EQ–5D–3L VAS score 
of 87.26 (±12.16).  The top five health states included 75.8% of the study sample.  The mean 
EQ–5D–3L index score and mean EQ–5D–3L VAS for those reporting the top five health states 
was 0.892 (±0.090) and 81.87 (±13.402), respectively. 
Table 2.2 Most common self–reported EQ–5D–3L health states 
Health state  n (%) EQ–5D–3L index 
score 
EQ–5D–3L VAS, 
mean (SD) 
11111 66 (30.7) 1.000 87.26 (12.16) 
11121 35 (16.3) 0.8271 82.74 (10.36) 
11112 22 (10.2) 0.8438 81.68 (7.76) 
11122 22 (10.2) 0.7998 75.68 (16.53) 
11221 9 (4.2) 0.8163 69.89 (11.932) 
21221 9 (4.2) 0.7778 66.56 (13.76) 
VAS Visual Analogue Scale; SD Standard Deviation 
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Figure 2.1 depicts the level of problems reported by MS caregivers for each dimension of 
the EQ–5D–3L.  One–fifth of the caregivers indicated having moderate problems in mobility and 
roughly 23% indicated so in performing usual activities.  Roughly half of the sample reported 
moderate pain or discomfort and a third indicated being moderately anxious or depressed.   
 
 
Convergent and discriminant validity 
The correlation matrix between the EQ–5D–3L, SF–12v2, and caregiver objective and subjective 
burden scale scores of the Montgomery burden scale is presented in Table 2.3.  For convergent 
validity, evidence of moderate to strong correlation was found between each pair of related 
domains of the EQ–5D–3L (EQ–5D–3L index and EQ–5D–3L VAS) and SF–12v2, with the 
exception of the relationship between EQ–5D–3L self–care and SF–12v2 BP domain (r = –
0.194, p <0.01).  Specifically, strong correlation was observed between EQ–5D–3L 
anxiety/depression and SF–12v2 MH domain (r = –0.619, p <0.01), EQ–5D–3L pain/discomfort 
and SF–12v2 BP domain (r = –0.594, p <0.01), and between EQ–5D–3L VAS and SF–12v2 GH 
domain (r = 0.651, p <0.01).  Moderate correlation was observed between related domains of the 
Mobility Self-care Usual activities Pain/Discomfort Anxiety/Depression
No problems 79.50% 93.50% 74.40% 47% 62.80%
Moderate problems 20% 5.60% 22.80% 49.80% 32.10%
Severe problems 0.50% 0.90% 2.80% 3.30% 5.10%
0%
20%
40%
60%
80%
100%
Fr
e
q
u
e
n
cy
Severe problems Moderate problems No problems
Figure 2.1 Level of problems reported on the EQ–5D–3L by MS caregivers  
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EQ–5D–3L and subscales scores of Montgomery burden measure.  Greater caregiver objective 
burden was associated with lower EQ–5D–3L index score (r = –0.320, p <0.01) and greater 
caregiver subjective burden score was also associated with lower EQ–5D–3L index score (r = –
0.342, p <0.01).  Greater caregiver objective burden was associated with lower EQ–5D–3L VAS 
score (r = –0.204, p <0.01) and greater caregiver subjective burden score was also associated 
with lower EQ–5D–3L VAS score (r = –0.198, p <0.01).  
When examining discriminant validity of the EQ–5D–3L, weak correlation was observed 
between most unrelated domains of the EQ–5D–3L and SF–12v2.  Weak and insignificant 
association was noted between EQ–5D–3L mobility and SF–12v2 MH (r = –0.004, p > 0.05), 
EQ–5D–3L self–care and SF–12v2 MH domain (r = –0.079, p > 0.05), and EQ–5D–3L usual 
activities and SF–12v2 MH domain (r = –0.079, p >0.05).  Though significant, a weak 
correlation was observed between EQ–5D–3L usual activities and SF–12v2 RE domain (r = –
0.199, p < 0.01) and between EQ–5D–3L mobility and SF–12v2 RE domain (r = –0.156, p 
<0.05). 
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Table 2.3 Correlation of the EQ–5D–3L domains with SF–12v2 and Montgomery burden scale 
 EQ–5D–3L 
Variablesa Mobility Self–care 
Usual 
activities 
Pain/ 
Discomfort 
Anxiety/ 
Depression 
EQ–5D–
3L Index 
EQ–5D–
3L VAS 
SF–12v2        
    Physical functioning –454** –.371** –.437** –.339** –.211** .461** .411** 
    Role physical –.342** –.317** –.431** –.402** –.319** .499** .501** 
    Bodily pain –.365** –.194** –.422** –.594** –.135* .515** .449** 
    General health –.307** –.230** –.402** –.471** –.231** .535** .651** 
    Vitality –.298** –.182** –.365** –.329** –.367** .485** .507** 
    Social functioning –.238** –.191** –.327** –.270** –.461** .436** .443** 
    Role emotional –.156* –.165* –.199** –.197** –.577** .386** .353** 
    Mental health –.004 –.079 –.124 –.174* –.619** .341** .358** 
    Physical component score (PCS–12) –.451** –.311** –.482** –.483** –.024 .469** .473** 
    Mental component score (MCS–12) –.025 –.062 –.120 –.149* –.616** .329** .348** 
Montgomery burden scale        
  Objective burden .080 .140* .135* .224** .344** –.320** –.204** 
  Subjective burden .107 .199** .191** .238** .351** –.342** –.198** 
VAS Visual Analogue Scale 
**p < 0.01, *p < 0.05 
 aValues noted represent Spearman's rank correlation coefficient 
Higher (better) scores on SF-12v2 subscales are associated with lower problems on the EQ-5D-3L domains as indicated by negative 
values of correlation coefficient 
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Known–groups validity 
Table 2.4 presents the results of known–groups validity of the EQ–5D–3L.  Caregiver EQ–5D–
3L index and EQ–5D–3L VAS scores varied with care recipients’ level of MS disability as 
reported by caregiver (as measured by CDDS).  The scores on the EQ–5D–3L significantly 
varied between caregivers providing support to care recipients with ‘severe to total disability’ 
versus those providing support to less disabled (‘mild to moderate disability’) care recipients.  
Post–hoc comparison indicated significant differences in EQ–5D–3L index (p <0.001) and EQ–
5D–3L VAS (p = 0.026) scores between caregivers supporting individuals with MS with ‘no 
walking disability’ and ‘severe to total disability’.  EQ–5D–3L index (p = 0.008) and EQ–5D–3L 
VAS (p = 0.018) scores were also significantly different for caregivers providing support to 
individuals with MS with ‘mild to moderate disability’ versus ‘severe to total disability’.   
 Greater caregiver age was significantly associated with lower EQ–5D–3L index score (r 
= –0.184, p = 0.007).  Although in the correct direction, greater caregiver age was not found to 
be significantly associated with lower EQ–5D–3L VAS score (r = –0.029, p = 0.674). 
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   Table 2.4 Differences in mean caregivers’ EQ–5D–3L health scores by care recipients’ level of MS disability status (CDDS) 
Care recipient disability status (CDDS) N EQ–5D–3L Indexa EQ–5D–3L VASb 
  Mean  
(SD) 
Median (Range) Mean 
 (SD) 
Median (Range) 
  No walking disability (1) 67 0.872 (0.160) 0.844  
(0.31–1.00) 
81.01 (14.79) 85.0  
(40.0–100.0) 
  Mild to moderate disability (2) 74 0.845 (0.129) 0.827  
(0.46–1.00) 
81.78 (11.86) 84  
(40.0–100.0) 
  Severe to total disability (3) 74 0.776 (0.200) 0.81  
(–0.04–1.00) 
74.66 (17.47) 80.00  
(20.0–100) 
  Post–hoc comparison 
(1) vs (2)  p = 0.079 p = 0.799 
(1) vs (3)  p < 0.001 p = 0.026 
(2) vs (3)  p = 0.008 p = 0.018 
CDDS Caregiver Determined Disease Steps 
VAS Visual Analogue Scale; SD Standard Deviation 
a Significant differences (p < 0.001) in EQ–5D–3L index by care recipient disability status 
b Significant differences (p = 0.028) in EQ–5D–3L VAS by care recipient disability status 
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Ceiling and floor effect 
Roughly 31% of the caregivers reported ‘no problems’ in all domains of the EQ–5D–3L 
(‘11111’) with an EQ–5D–3L index value of 1.00, indicating presence of ceiling effects.  None 
of the caregivers indicated having extreme problems in all domains of the EQ–5D–3L (‘33333’), 
indicating absence of floor effects.  The EQ–5D–3L VAS was also examined for presence of 
floor and/or ceiling effect.  Only 2.3% of the study sample reported the best possible score of 
100 and none reported the lowest possible score of 0 with EQ–5D–3L VAS, indicating absence 
of floor and ceiling effects.  
Internal consistency reliability  
Table 2.5 presents results of reliability analysis of the EQ–5D–3L.  The Cronbach’s α of the EQ–
5D–3L descriptive system was 0.72.  In addition, the value of corrected item–total correlation for 
each item was higher than the standard acceptable value of 0.20, ranging between 0.26 and 0.67. 
Table 2.5 Reliability analysis of the EQ–5D–3L 
EQ–5D–3L domains Corrected item–total correlations  
Mobility  0.601 
Self–care  0.556 
Usual activities 0.668 
Pain/discomfort 0.472 
Anxiety/depression 0.258 
Cronbach’s alpha = 0.72 
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DISCUSSION 
Health utilities are integrated into economic evaluations of treatments/interventions to inform 
decisions pertaining to prioritization of healthcare dollars.  There has been an increased attention 
on the relevance of including caregiver health utilities (‘spillover effects’) in health economic 
evaluations along with those of patients (Brouwer, 2006; Wittenberg & Prosser 2013).  Given 
that there is substantial evidence to suggest that an illness not only impacts diseased individuals 
but also their family members (Prosser et al., 2014), there is a need to assess health utilities 
among caregivers of individuals suffering from chronic debilitating diseases like MS.  
Preference–based measures such as the EQ–5D–3L are commonly employed to assess health 
utilities (EuroQoL 1990).  The brevity (5 items) and low respondent burden of the EQ–5D–3L 
makes it a viable candidate for application across different populations including caregivers.  In 
order to utilize the EQ–5D–3L for health utility assessment among MS caregivers, evidence for 
its satisfactory psychometric profile in this population is necessary.  This study is the first to 
evaluate psychometric properties of the EQ–5D–3L in a sample of caregivers of individuals with 
MS.  Specifically, construct validity in terms of convergent, discriminant, and known–groups 
validity, and other measurement properties including ceiling and floor effect, and internal 
consistency reliability of the EQ–5D–3L were evaluated.   
Convergent validity was assessed by determining the association between theoretically 
related domains of the EQ–5D–3L and SF–12v2 and between EQ–5D–3L index and 
Montgomery caregiver burden subscale scores.  Except for the relationship between  EQ–5D–3L 
self–care and SF–12v2  BP domain, where a weak yet significant correlation was observed, all 
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other relationships among theoretically related EQ–5D–3L and SF–12v2 domains were as 
hypothesized.  Further, we found moderate association between the EQ–5D–3L index scores and 
caregiver subjective and objective burden subscale scores.  A weak relationship between EQ–
5D–3L self–care and SF–12v2 BP domain may be attributed to the intrinsic differences in the 
tasks evaluated as per the self–care and BP domains of these measures.  The EQ–5D–3L self–
care domain assesses the extent of problems experienced while caring for self, washing or 
dressing; however, the SF–12v2 BP domain ascertains the extent to which pain interferes in 
normal work outside the home and house work.  The EQ–5D–3L self–care refers to tasks 
conducted in the household such as bathing and dressing; whereas, the SF–12v2 BP refers to 
pain interference in normal tasks outside the house.  Further, it was also observed that the self–
care and pain/discomfort domains of the EQ–5D–3L itself were viewed differently by MS 
caregivers.  The proportion of caregivers indicating no problems in the EQ–5D–3L self–care was 
93%; while only 47% indicated having no problems with EQ–5D–3L pain/discomfort.  
Therefore, it appears that caregivers perceived BP and self–care domains differently which can 
explain the low correlation between the two domains of the EQ–5D–3L and the SF–12v2 as 
found in our study.   
In terms of discriminant validity, we noted weak association between theoretically 
unrelated domains of the EQ–5D–3L and SF–12v2.  A weak but significant correlation between 
the EQ–5D–3L usual activities and SF–12v2 RE domain (r = –0.199, p < 0.01).  Similarly, a 
weak but significant correlation was also found between the EQ–5D–3L mobility and SF–12v2 
RE domain. 
Known–groups validity was evaluated by assessing the variation in caregiver EQ–5D–3L 
index and EQ–5D–3L VAS scores across care recipient disability levels.  We found significant 
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differences in EQ–5D–3L index and EQ–5D–3L VAS scores of caregivers of individuals with 
‘no walking disability’ versus caregivers of individuals with ‘severe to total disability’, and 
between caregivers of individuals with ‘mild to moderate disability’ versus ‘severe to total 
disability’.  Our results point towards the ability of the EQ–5D–3L to successfully distinguish 
between groups of caregivers of individuals with varying level of MS disability based on 
caregiver EQ–5D–3L index and EQ–5D–3L VAS scores.  We also found a negative correlation 
between caregiver age and EQ–5D–3L index score which is also indicative of good known–
groups validity of the instrument.  Caregiver age has been reported to be associated with lower 
HRQOL among MS caregivers (Aronson, 1997; Buchanan & Huang, 2011; Patti et al., 2007).  
For example, Buchanan and Huang (2011) found increasing caregiver age to be associated with 
reduced HRQOL among MS caregivers.  Similar to these studies in the MS caregiver literature, 
we found lower EQ–5D–3L index scores among older caregivers.  The results of known–groups 
validity assessment suggest that caregiver health utility is related to age of the caregivers and 
disability status of the individuals to whom they provide support.  As a result, it is expected that 
greater the severity of disability status among care recipients, lower the health utility among MS 
caregivers.  Further, it is also predictable that as MS caregivers age, their health state utilities 
(EQ–5D–3L index) decrease.  Overall, these findings suggest that the EQ–5D–3L demonstrated 
the ability to detect differences in MS caregivers with respect to age and care recipient disability 
status, thereby generating confidence for employing the instrument in future studies to assess 
health status in this population. 
Although floor effects were found to be absent, ceiling effects were reported for the EQ–
5D–3L.  Prior studies examining the psychometrics of the EQ–5D–3L among other populations 
have also reported presence of ceiling effects (Pickard et al., 2004; Khanna et al., 2013b; Shafie 
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et al., 2011).  In our study, several caregivers reported being in the best health state (‘11111’) of 
the EQ–5D–3L despite the significant burden experienced by them (as measured by Montgomery 
burden scale).  The caregiver objective and subjective burden subscale scores for the subset of 
caregivers who reported being in perfect health (‘11111’ EQ–5D–3L) were lower than burden 
scores of caregivers reporting not being in perfect health.  Further, though the SF–12v2 PCS and 
MCS subscale scores were significantly higher (better) for the subset of caregivers with perfect 
health (‘11111’ EQ–5D–3L) than those who reported being in less than perfect health, the PCS 
and MCS scores did not reflect close to perfect health.  To further understand these findings, we 
also compared the SF–6D utility scores (obtained from the SF–12v2) between caregivers who 
reported being in perfect health on the EQ–5D–3L versus those who did not.  We found that SF–
6D utilities were higher (better) among those in perfect health versus not.  To accomplish this 
comparison, SF–6D scores were generated from the responses on the SF–12v2 using the 
OptumInsight SF Health OutcomesTM Scoring Software.  Though the aforementioned 
examination of caregiver burden subscale scores, SF–12v2 PCS, MCS, and SF–6D scores for a 
subset of caregivers with perfect health on the EQ–5D–3L provides some insight into the results 
pertaining to EQ–5D–3L ceiling effects, further studies are needed.  Evidence of ceiling effect 
may be more problematic if the EQ–5D–3L is used for evaluative purposes in a longitudinal 
caregiver intervention.  Our findings concerning ceiling effects suggest that the EQ–5D–3L may 
not be a useful measure to assess change in health utility over time.  The EQ–5D–5L could be a 
viable alternative for studies implementing a longitudinal design as it was developed with the 
intent of reducing ceiling effects that are present in the EQ–5D–3L (Herdman et al., 2011).  The 
EQ–5D–5L has shown to have better measurement properties than the EQ–5D–3L, specifically 
in terms of lower rate of ceiling effect (Kim et al., 2011).  Although a valuation study for the 
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EQ–5D–5L in the US population has not been conducted and a directly elicited value set is 
currently not available, future researchers can take advantage of the EQ–5D–5L cross walk value 
set available for the US population (van Hout et al., 2012).   
The study findings must be evaluated in the light of a few important weaknesses.  
Although this study evaluated convergent, discriminant, and known–groups validity to provide 
evidence for construct validity of the EQ–5D–3L among MS caregivers, the cross–sectional 
nature of the study precluded assessment of criterion validity (e.g. predictive validity) of the 
instrument.  Further, because of the cross–sectional study design, we could not assess the test–
retest reliability of the EQ–5D–3L.  For the purpose of this study, we recruited a convenience 
sample of MS caregivers by seeking assistance from a volunteer MS patient registry.  The non–
probability sampling design that was employed to gain access to the caregiver population for the 
survey is likely to limit the generalizability of the study findings. 
Conclusion 
The results of this study allude towards acceptable psychometrics of the EQ–5D–3L among MS 
caregivers.  A moderate to strong correlation observed between theoretically related constructs of 
the EQ–5D–3L and SF–12v2 instrument and EQ–5D–3L and Montgomery burden scale 
provided evidence of convergent validity of the EQ–5D–3L.  Weak correlation between 
unrelated constructs of EQ–5D–3L and SF–12v2 highlighted an acceptable discriminant validity 
of the EQ–5D–3L.  The EQ–5D–3L was able to distinguish MS caregivers based on care 
recipient disability status, indicating an acceptable known–groups validity.  Although floor 
effects were absent, we did observe ceiling effects for the EQ–5D–3L index scale.  Floor and 
ceiling effects were absent for the EQ–5D–3L VAS.  The internal consistency reliability of the 
EQ–5D–3L was found to be acceptable.  The EQ–5D–3L presents a viable approach to health 
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state preference measurement among MS caregivers; however, its acceptability and use in 
longitudinal studies needs further investigation.   
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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic neurodegenerative disease characterized by relapses and 
remission (Grima et al., 2000; Mohr & Cox, 2001).  MS affects ~572,000 individuals in the 
United States (US) (Campbell et al., 2014) and is associated with significant economic burden.  
The total all–cause healthcare costs of MS has been found to range between $8,528 and $54,244 
per patient per year (Adelman et al., 2013).  The financial burden of MS is largely driven by 
direct non–medical costs including those of assistive devices, aids, formal and informal care, and 
indirect costs associated with loss in productivity (Naci et al., 2010).   
Incomplete recovery from relapses among individuals with MS leads to disability and 
disease progression.  Mobility impairment is one of the most disabling effects of MS that 
increases dependence on caregivers and other family members for routine activities.  The 
progressive and unpredictable nature of MS and the early age of onset places a significant burden 
among care recipients and their families (henceforth referred to as ‘caregivers’) (Arnett, 2007; 
Benito‐León et al., 2003; Buchanan & Huang 2011; Gupta et al., 2012).  Caring for an individual 
with MS is not only burdensome, but also associated with poor health outcomes among 
caregivers (Arnett 2007; Benito–León et al., 2003; Buchanan & Huang 2011; Gupta et al., 2012; 
Patti et al., 2007).   
The United States (US) panel on cost–effectiveness in health and medicine recommended 
inclusion of HRQOL of significant others (caregivers) in economic evaluation of healthcare 
treatments/interventions (Gold et al., 1996).  Additionally, there is a growing interest in 
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integration of informal caregivers’ health gains/losses (‘spillover effects’) in economic 
evaluation of treatments/interventions (Al–Janabi et al., 2011; Koopmanschap et al., 2008; 
Wittenberg & Prosser, 2013) due to the well–documented impact of a family member’s illness 
on HRQOL of caregivers.  As a result of the burden imposed by MS on both care recipients and 
their caregivers, there is a need to consider MS caregivers’ ‘spillover effects’ in economic 
evaluation of MS treatments/interventions.  One outcome that enables researchers to capture the 
spillover effects of caregiving is health utility.  
Health utility represents an individual’s overall valuation (preference) of quality of life 
for a health state summarized into an index that typically ranges between 0 (death) and 1 (perfect 
health) (Fisk et al., 2005; Prosser et al., 2003; Tsevat, 2000).  Health utility estimates are used to 
calculate quality–adjusted life years (QALY), which are integral to health economic evaluations 
such as cost–utility analyses (CUA) (Gold et al., 1996).  Health utility can be assessed by both 
direct and indirect methods.  Direct health utility measurement comprises of standard gamble 
technique (SGT), time trade–off (TTO) or rating scales to elicit utility/preference for health 
states; whereas, indirect assessment entails application of scoring algorithms on responses to 
multi–attribute health utility questionnaires to generate health utility scores (Bennett & Torrance, 
1996).  
A few studies have estimated health utility among caregivers of individuals with MS 
(Acaster et al., 2013; Argyriou et al., 2011; Gupta et al., 2012).  In their study of unpaid 
caregivers of individuals with MS, Acaster et al. (2013) found significantly lower HRQOL 
(utility) among MS caregivers as compared to matched controls in the United Kingdom (UK) 
population.  In another study, lower health utility scores were observed among MS caregivers as 
compared to controls in the Greek population (Argyriou et al., 2011).  To date, only one study in 
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the US has examined health utility among caregivers of individuals with MS (Gupta et al., 2012).  
When comparing utility values of non–caregiver controls with MS caregivers in the US, Gupta et 
al. (2012) found lower values in the latter group as compared to the former.  Although Gupta et 
al. (2012) were the first to examine health utility values among MS caregivers in the US, they 
did not assess the underlying factors predicting health utility in this population.  For the purposes 
of their study, Gupta et al. (2012) used a pre–existing survey data, i.e., the National Health and 
Wellness Survey, which does not assess information regarding care recipient’s level of MS 
disability, time from MS diagnosis, care recipient age, and care recipient’s relationship with the 
caregiver.  The role of psychosocial factors (e.g. coping and social support) and their impact on 
health utility of MS caregivers were also not assessed in their study.  Studies in caregiving 
literature in general have identified caregivers’ perceived level of social support and coping 
strategies as significant predictors of their health (Khanna et al., 2011; Khanna et al., 2013a; 
Markowitz et al., 2003; Yu et al., 2013; Zhang et al., 2013).  In order to explicate the burden of 
MS caregiving, it important to comprehend the impact of psychosocial predictors along with care 
recipient disability factors on caregiver health utility.   
This study utilized a modified stress, coping, and appraisal model developed by Yates 
and colleagues as a guiding framework to examine predictors of health utility among caregivers 
of individuals with MS (Yates et al., 1999).  The key components of the original model proposed 
by Yates and colleagues includes – 1) primary stressors (cognitive impairment, functional 
disability and problem behaviors), 2) primary appraisal (assessment of need for care), secondary 
appraisal (overload/burden), 3) mediators – (formal service use, global mastery, quality of 
caregiver–care recipient relationship, and emotional support available to caregivers), and 4) 
outcome (depression).  Researchers have adapted Yates and colleagues’ model to study 
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caregiving population across other disease areas (Cassado & Sacco, 2011; Chappell & Reid, 
2002; Goldsworthy & Knowles, 2008; Khanna et al., 2011).  For example, Cassado & Sacco 
(2011) used a modified version of the model developed by Yates and colleagues to examine 
factors affecting burden among family caregivers of elderly Korean Americans.  They reported 
presence of a large family support network, greater family agreement, and care management 
self–efficacy as correlates of lower caregiver burden.  Chappell and Reid (2002) examined well–
being among caregivers of individuals with dementia using a revised Yates and colleagues’ 
model.  Perceived social support, burden, self–esteem, and hours of informal were found to 
impact caregiver well–being.   In our study, the original framework proposed by Yates and 
colleagues was adapted according to the caregiving process specific to MS caregivers in this 
study.  Figure 3.1 depicts the conceptual framework utilized for the purpose of this study.   
 
Figure 0.1 Study model 
 
Mobility impairment/disability among individuals with MS is associated with diminished 
ability to perform activities related to self–care (Finlayson & Denend, 2003), resulting in greater 
need for assistance from caregivers (Aronson et al., 1996; Carton et al., 2000; O’Brien, 1993; 
O’Brien, 1995).  As progressive disability among individuals with MS is acknowledged as an 
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indicator of stress among caregivers (Dunn, 2010; Hakim et al., 2000), the current study 
examined care recipient MS disability status as a primary stressor among MS caregivers.  Yates 
and colleagues assessed primary appraisal in terms of care recipient’s need for assistance by the 
caregiver i.e. hours of informal care.  Primary appraisal refers to the process by which the 
individual (caregiver) evaluates the situation for any potential concerns/challenges, e.g. 
caregiver’s evaluation of the situation according to the commitment required as a caregiver 
(Folkman, 1984).  The current study conceptualized primary appraisal as objective caregiver 
burden, which is defined as ‘the perceived infringement or disruption of tangible aspects of 
caregiver’s life’.  As opposed to simply assessing need for assistance in terms of hours of 
informal care provided to the care recipient (Yates et al.,1999), this study assessed the impact of 
caregiving on several tangible aspects of caregiver’s life such as time available for recreational 
activities, privacy, and finances.  In terms of intermediary factors, the current study included 
social support and coping strategies employed by caregivers.  Greater reliance on adaptive 
coping strategies and higher social support has been found to be associated with lower distress 
and better adaptation among MS caregivers (Pakenham 2001; Pakenham 2002; Pakenham 2005).  
Pakenham and Bursnall (2006) found better adjustment among caregivers of individuals with MS 
to be related to greater reliance on approach coping, lesser reliance on avoidant coping, and 
greater social support.  In another study, Bambara et al. (2014) highlighted the importance of 
improving social support among MS caregivers, particularly among caregivers of those with 
greater MS severity.  Due to the role of social support and coping in adjustment/adaptation 
among MS caregivers, these factors were included as intermediary factors in the modified model.  
Various adaptational outcomes including depression, health status, well–being, physical and 
mental health, and quality of life have been examined among MS caregivers (Chappell & Reid, 
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2002; Goldsworthy & Knowles, 2008; Pearlin et al., 1990; Yates et al., 1999).  The current study 
assessed health utility among MS caregivers as an outcome in the modified model. 
Given that limited information pertaining to health utility among MS caregivers in the US 
is currently available, this study aimed to estimate health utility among caregivers of individuals 
with MS in the US and identify the factors affecting health utility in this caregiver population.  
Using an adapted stress, coping, and appraisal model as a guiding framework, direct and indirect 
relationships among care recipient disability status, caregiver objective burden, perceived 
caregiver social support, caregiver subjective burden, coping strategies, and health utility among 
MS caregivers were studied.  In addition, health utility scores among MS caregivers were 
compared with US population norm values. 
The following hypotheses were tested in this study.  After adjusting for age and gender, 
health utility scores among MS caregivers will be lower than the norm–based health utility 
scores of the general US population.  Care recipient’s disability status will have an adverse 
influence on objective and subjective caregiver burden such that, greater the disability level of 
care recipients with MS, higher the burden among caregivers.  Care recipient’s disability status 
will adversely influence health utility such that, greater the disability level of care recipients with 
MS, lower the health utility among caregivers.  Greater the disability level of care recipients, 
greater the use of both problem focused and interpersonally supportive and avoidant and critical 
coping strategies by the caregivers.  Greater the disability level of care recipients, greater the 
need for social support by the caregivers.  Higher the objective burden among caregivers, higher 
their subjective burden and lower their health utility.  Greater the social support perceived by 
caregivers of individuals with MS, lower the subjective burden among caregivers and higher 
their health utility.  Greater use of problem focused and interpersonally supportive coping 
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strategies and lower use of avoidant and critical coping strategies will be related to lower 
subjective burden and higher health utility among MS caregivers.  Caregivers who experience 
lower objective and subjective burden will have higher health utility.   
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RESEARCH DESIGN AND METHODS 
 
Study design 
This study utilized a cross–sectional, non–experimental study design by means of a web–based 
self–administered survey that was distributed to a convenience sample of caregivers of 
individuals with MS.  
Study sample and data source 
The target population for this study included informal caregivers of adults (≥18 years of age) 
with MS in the US.  A convenience sample of informal caregivers of individuals with MS was 
recruited using assistance from a MS patient registry, i.e., the North American Research 
Committee on Multiple Sclerosis (NARCOMS).  NARCOMS is a volunteer registry of over 
37,000 MS patients, initiated by the consortium of MS centers (CMSC) in 1993.  Registry 
participants (individuals with MS) were requested to identify their caregiver (primary support 
provider) or ‘the person most often available to assist or support when needed, regardless of the 
level and frequency of support involved’.   
Sample size 
Determination of an acceptable sample size for the study was based on the analysis technique 
deemed appropriate to address the study objectives.  Path analysis was used to identify 
determinants of health utility among caregivers of individuals with MS.  The direct and indirect 
relationships between variables in the conceptual framework were also examined (Figure 3.1).  
According to guidelines suggested by Kline (2011), a minimum sample of 150 is needed when 
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there are ≤ 7 constructs in a model Kline (2011).  A sample size of 250 was deemed appropriate 
to conduct path analysis.   
Data collection 
A cover letter was mailed to NARCOMS registry participants (individuals with MS) requesting 
them to identify their caregiver (primary support provider) regardless of the level and frequency 
of support involved.  To protect the identity of registry participants, sample selection and survey 
mailing was carried out by NARCOMS.  Along with the cover letter, registry participants were 
also sent a separate survey invitation letter addressed to their caregiver requesting their study 
participation.  The link to the survey site (Qualtrics) was provided in the survey invitation letter.  
The survey was programmed using Qualtrics, a web–based tool used for designing and 
distribution of surveys over the Internet.  A $15 Amazon gift card was offered to caregivers as an 
appreciation of their study participation.  An approval from the University of Mississippi’s 
Institutional Review Board (UM–IRB) was obtained under exempt status.  
The survey contained four sections. Section I included measures concerning caregiver’s 
health and well–being, caregiving experience, social support, and coping strategies.  Section II 
assessed disease severity (disability status) of the care recipient.  Section III ascertained 
demographic characteristics of the caregiver and the care recipient.  Section IV assessed 
information about health state preferences of caregiver (primary support provider).   
Study measures 
The EuroQoL–Five–Dimensional Questionnaire (EQ–5D–3L).  EQ–5D–3L is a preference–
based measure of HRQOL that consists of a descriptive system and a visual analogue scale (EQ–
5D–3L VAS) (EuroQoL, 1990).  There are five dimensions of the EQ–5D–3L descriptive 
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system– mobility, self–care, usual activities, pain/discomfort, and anxiety/depression, with 3 
levels for each dimension– 1 = “no problems”, 2 = “some problems”, and 3= “extreme 
problems”.  The EQ–5D–3L VAS is a vertical 20 cm line where, end–points are marked from 0 
= “worst imaginable health state” and 100 = “best imaginable health state” (EuroQoL, 1990).  
The information obtained from the self–reported health states was converted to a single summary 
index using the scoring algorithm developed by Shaw et al. (2005).   
Medical Outcomes Study Short–Form Health Survey version 2 (SF–12v2).  The web version of 
the standard SF–12v2 was used to determine physical and mental health status of caregivers.  
SF12v2 is a 12–item measure derived from the SF–36 health survey (Ware et al., 1996).  SF–
12v2 assesses eight domains of health including physical functioning (PF), role physical (RP), 
bodily pain (BP), general health (GH), vitality (V), social functioning (SF), role emotional (RE), 
and mental health (MH).  Scores on these domains are combined to calculate summary scores – 
physical component score (PCS) and mental component score (MCS).  Responses on the SF–
12v2 were transformed onto a 0–100 scale (higher scores reflect better health) using the SF–12v2 
scoring software (Ware et al., 2002).   
Montgomery Burden Scale.  The 22–item Montgomery burden scale was used to measure burden 
among MS caregivers (Montgomery, 1985).  A nine–item scale was used to assess objective 
burden on a 5–point scale with the rating system: a lot more (better); a little more (better); the 
same; a little less (worse); a lot less (worse).  A thirteen–item scale was used to assess subjective 
burden among MS caregivers measured on a 5–point scale with the rating system: rarely/never; a 
little of the time; sometimes; often; most of the time.  Modifications were made to the subjective 
burden subscale based on the population of interest (i.e. caregivers).  For example, the statement 
‘I feel nervous and depressed about my relationship with my (relative)’ in the original subjective 
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burden subscale was changed to ‘I feel nervous and depressed about my relationship with the 
person that I care for’ for the purpose of the current study.  The statement ‘I feel that my 
(relative) makes requests which are over and above what s/he needs’ was changed to ‘I feel that 
the person that I care for makes requests which are over and above what s/he needs’.  The 
Cronbach’s alpha was 0.89 and 0.70 for caregiver objective burden subscale and revised 
caregiver subjective burden subscale, respectively.   
Multidimensional Scale of Perceived Social Support (MSPSS).  The 12–item MSPSS scale was 
used to assess caregivers’ perception of social support from various sources including family, 
friends, and significant others (Zimet et al., 1988).  Perceived social support among caregivers 
was assessed on a 7–point Likert–type scale from 1= “very strongly disagree” to 7 = “very 
strongly agree”.  
Coping with Multiple Sclerosis Caregiving Inventory (CMSCI).  The 34–item coping with MS 
caregiving inventory was used to assess coping strategies employed by MS caregivers.  
Caregivers were asked to indicate their main problem associated with caregiving encountered 
during the past month.  Caregivers were asked to rate the level of stress caused due the identified 
problem on a 7–point linear numeric scale, where 1= “not at all stressful” and 7 = “extremely 
stressful”.  The caregivers were provided with a set of coping strategies (the coping inventory) 
and asked to indicate how often they used these coping strategies to handle their main caregiving 
problem on 5–point verbal frequency scale, where 0 = “does not apply/never”, 1 = “rarely”, 2 = 
“sometimes”, 3 = “often”, 4 = “very often”.  The CMSCI provides five subscale scores – 
avoidance, practical assistance, supportive engagement, criticism and coercion, and positive 
reframing.  The scales were summarized into two higher–order dimensions of coping – problem 
focused and interpersonally supportive coping (including supportive engagement, positive 
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reframing, and practical assistance) and avoidant and critical coping (including avoidance and 
criticism and coercion) (Pakenham, 2002). 
Caregiver–Determined Disease Steps (CDDS).  Patient determined disease steps (PDDS) is a 
measure used to assess MS related functional disability in care–recipients.  After collaborating 
with NARCOMS, the PDDS was adapted into a caregiver–administered instrument where the 
caregiver can respond to indicate disability among care recipients (Hohol et al., 1995; Hohol et 
al., 1999).  The PDDS was revised as caregiver–determined disease steps (CDDS), measured on 
an 8–point scale, where 0 = “normal”, 1 = “mild disability”, 2 = “moderate disability”, 3 = “gait 
disability”, 4 = “early cane”, 5 = “bilateral support”, 6 = “wheelchair”, 7 = “wheelchair/scooter”, 
8 = “bedridden”.  Description of each category was provided in the survey. 
Socio–demographic characteristics of caregivers and care recipients  
Information pertaining to socio–demographic characteristics of caregivers including age, gender, 
race/ethnicity, education, marital status, income, employment status, co–residence with care–
recipient, their relationship with the care recipient, whether or not they assist the care recipient 
with injections, places they have taken the care recipient for treatment–related injections, was 
obtained.  Additionally, information about care recipient’s age, gender, race/ethnicity, years 
since diagnosis of MS, type of MS, health insurance coverage, whether or not on prescription 
medications for MS, and route of medication administration was collected.  Information about 
weekly hours of assistance provided to care recipients was also obtained. 
Data management 
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Survey data collected was downloaded as Microsoft® Excel file for data management and 
cleaning.  Subsequently, the data was imported to Statistical Package for Social Sciences (SPSS) 
Statistics version 22.0 (IBM, Corporation, Armonk, NY, US) for analyses.   
Missing data.  Data were examined for extent and pattern of missing data.  Responses with more 
than 15% missing data on the main study variables were excluded from analyses.  Case mean 
substitution was utilized to replace missing values on main study variables with less than 15% 
missing data (Schafer & Graham 2002).  The web–version of the EQ–5D–3L was used in this 
study, which restricts respondents from proceeding further if there are incomplete responses on 
any dimension.  As a result, complete data on EQ–5D–3L was received.  Missing data for SF–
12v2 responses was accounted for by the missing score handling technique (Missing Score 
Estimation) developed by Quality Metric™ OptumInsight. 
Assumptions.  For path analysis, normality of the data is a critical assumption.  Additionally, data 
that exhibit kurtosis (peakedness or flatness of the distribution when compared to normal 
distribution) present difficulty in analysis using SEM (Byrne, 2009).  Data were examined for 
normality by plotting Q–Q or normal probability plots and formal tests of normality including 
Kolmogorov–Smirnov and Shapiro–Wilks tests.  Individual variables were tested for normality 
using an index for univariate kurtosis.  Values >5.00 are indicative of non–normally distributed 
data.  An index of multivariate kurtosis – Mardia’s normalized estimate of multivariate kurtosis 
and its critical ratio (CR) was also assessed.  Large positive and negative values are suggestive of 
kurtosis.  Assessment of outliers was also conducted by calculating a squared Mahanalobis 
distance (D2) for each case.  Outliers were detected by identifying a case with D2 value that stood 
apart from all other D2 values.   
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Data analyses  
Data analyses were conducted using SPSS version 22.0, AMOS version 22.0 (IBM Corporation, 
Armonk, NY, US), and Mplus version 7.11 (Muthén & Muthén, Los Angeles, CA).  Descriptive 
analyses and scale reliability analyses were carried out using SPSS v22.0.  AMOS v22.0 was 
used to examine the assumption of normality, skewness, and kurtosis in the variables in the path 
model.  Upon identifying a violation of normality assumption for the dependent variable 
(caregiver health utility) in our study, AMOS was found to be unsuitable for carrying out path 
analysis as it uses the maximum likelihood (ML) based estimation technique that is not robust to 
violation of normality assumption.  The maximum likelihood estimator with robust standard 
errors (MLR) estimator in Mplus is robust to violation of normality assumption and was used to 
conduct path analysis.  All hypotheses were tested at 0.05 level of statistical significance. 
Sample description.  Frequencies and percentages, and means and standard deviations were 
calculated for categorical and continuous variables, respectively.  Association between 
continuous variables was determined using spearman rank correlation coefficient.  Comparison 
of proportions was conducted using chi square test (χ2).  Summated scale scores were computed 
for all study measures.  Scale reliability was estimated using Cronbach’s alpha (α) (≥0.70), as 
appropriate for all study measures.   
Caregivers’ responses on the EQ–5D–3L health states were converted to a single 
summary index using the scoring algorithm developed by Shaw et al. (2005).  The currently 
available value set for US includes 4,048 responses based on the TTO valuation method (Luo et 
al., 2005).  EQ–5D–3L index values were compared to norms of the US population using one 
sample t–test.  Variation in health utility values across sample characteristics was compared 
using Kruskal Wallis ANOVA.   
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Path analysis is an application of structural equation modeling (SEM) technique that 
employs a confirmatory/hypothesis testing approach to examine the direct and indirect 
relationships among variables.  Figure 3.2 depicts the path model for this study, where observed 
variables are represented by rectangles and error (residual) associated with each endogenous 
variable being represented by circles.  The error (residual) attached to each endogenous variable 
represents the unexplained variance in the endogenous variable.  Path analysis assumes that 
scores on exogenous variables are perfectly reliable because there are no errors associated with 
them (Dugard et al., 2010).   
 
Figure 0.2  Path analysis model: Determinants of health utility among MS caregivers 
Problem_inter_suppcoping Problem-Focused and Interpersonally Supportive Coping; 
avoidance_critical_coping Avoidance and Critical Coping; CDDS Caregiver Determined Disease 
Steps; CG_health_utility Caregiver Health Utility 
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Model identification.  First, the number of data points was calculated using the formula k(k+1)/ 
2, where k is the number of observed variables.  Based on 7 observed variables (i.e. k = 7), there 
were 28 data points in this study.  Next, the number of free parameters for the path model was 
calculated by adding the number of direct effects on endogenous variables, covariances and the 
residuals.  The model had 19 direct effects on endogenous variables, 1 covariance between two 
error terms, and 6 residuals, which gives a total of 26.  In addition, a constant was be estimated.  
The difference between the known parameters and the unknown parameters (free parameters) 
revealed an overidentified model (Dugard et al., 2010; Kline, 2011). 
Path analysis using the MLR estimator was carried out using Mplus to estimate and 
quantify the hypothesized relationships.  The MLR estimator in Mplus is robust to violation of 
normality assumption in the data.  In addition, bootstrapping using 10,000 re–samples was used 
as an aid to non–normal data.  The model parameter estimates were examined to determine if the 
direction of the relationships are as hypothesized in the conceptual framework i.e. in accordance 
with the underlying theory (Byrne, 2009).  Statistical significance of the parameter estimates was 
examined using sobel test and bias–corrected bootstrap confidence intervals.  Model fit was 
ascertained using overall chi–square (χ2) and the degrees of freedom (df).  Due to the limitations 
associated with the χ2 statistic, additional fit statistics including Comparative Fit Index (CFI), 
Tucker Lewis Index (TLI), Root Mean Square Error of Approximation (RMSEA), and 
standardized root mean square residual (SRMR) were used to determine model fit.  The CFI and 
RMSEA are indicated as the most frequently used fit indices, and therefore are reported in this 
study (Ullman, 2006).  An insignificant χ2 at 0.05 threshold and CFI ≥ 0.95, RMSEA <0.05 and a 
small SRMR are considered to be indicative of good fit between the data and the hypothesized 
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model (Hu & Bentler, 1999).  Modification indices (MIs) were used to detect model 
misspecification and improve fit.   
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RESULTS 
 
Description of the study sample 
 
Out of the 221 responses received, 6 responses had greater than 15% missing data on main study 
variables and were excluded from the analyses.  Missing data on responses to the SF–12v2 (n = 
3) was accounted for by the MSE developed by Quality Metric™ OptumInsight.  The final study 
sample comprised of 215 responses from MS caregivers (primary support providers).  Table 3.1 
describes the demographic characteristics of MS caregivers and care recipients.  The majority of 
caregivers were male (60.8%), White/Caucasian (87.9%), and had a mean age of 56.5 (±13.7) 
years, respectively.  Roughly 59.1% of the caregivers had some college degree.  In terms of the 
relationship with the care recipient, more than three–fourths of caregivers were either a spouse or 
significant other of the care recipient with MS.  A large majority of caregivers were married 
(78.1%) and resided with the care recipient (89.8%).  Roughly one–third of the caregivers had an 
annual family income of $49,000 or less.  Almost all (97.2%) of the caregivers reported that care 
recipients had some form of health insurance.  On average, caregivers were providing care since 
15.6 (±9.6) years and 36.3% of those spent 20 hours/week or more looking after an individual 
with MS.   
Most care recipients were female (77.7%), White/Caucasian (93.5%), and had an average 
age of 57.6 (±10.4) years, respectively.  More than one–third of the care recipients were reported 
having mild to moderate disability, while a similar proportion were reported to be severely or 
totally disabled.  Over half of the care recipients were reported to have relapsing–remitting MS, 
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followed by secondary–progressive MS (20.6%), primary–progressive MS (15.0%), and 
progressive–relapsing MS (6.1%).  More than two–third of the care recipients were indicated as 
being prescribed with MS medication(s).  Roughly 51% of the caregivers indicated that the 
individual that they provided care for was prescribed with oral prescription medications for MS 
and 59.2% reported that the care recipient was taking prescription medications via injection.  
Two–fifths of the caregivers reported assisting their care recipients with injections.  Almost one 
in four caregivers indicated that they accompany their care recipient to an infusion center, 17.5% 
accompanied to a hospital, and 16.5% to a physician’s office. 
Table 3.1 Demographic characteristics of multiple sclerosis (MS) caregivers and care recipients 
Characteristic n % 
Caregiver characteristic   
Gender   
  Male 130 60.75 
  Female 84 39.25 
Age, mean (sd) 56.5 13.65 
Race/Ethnicity   
  African American/Black 10 4.7 
  White/Caucasian 189 87.9 
  Other* 16 7.4 
Marital Status   
  Never Married 19 8.8 
  Married 168 78.1 
  †Other 28 13.1 
Education level   
  Less than high school 3 1.4 
  High school or technical school 30 14.0 
  College degree 127  59.1 
  Masters degree 33 15.3 
  Doctoral degree 12 5.6 
  Professional degree 9 4.2 
Employment Status   
  Employed/self–employed full time  102 47.4 
  Employed part–time 18 8.4 
  Other‡ 94 43.8 
Income   
  <$15,000 16 7.4 
  $15,000–$29,999 19 8.8 
  $30,000–$49,999 37 17.2 
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  $50,000–$100,000 68 31.6 
  Over $100,000 37 17.2 
  Don’t wish to answer 38 17.7 
Relationship to the care recipient   
  Spouse/Significant other 164 76.3 
  Parent 16 7.4 
  Child 14 6.5 
  Friend/Neighbor 11 5.1 
  Other 8 3.7 
Caregiving assistance (hours/week)   
  ≤5 hours 65 30.2 
  6–10 hours 29 13.5 
  11–15 hours 26 12.1 
  16–20 hours 17 7.9 
  ≥20 hours 78 36.3 
Care years, mean (sd) 15.6 9.57 
Living with care recipient   
  Yes  193 89.8 
  No 22 10.2 
Assist with injections   
  Yes 38 40.0 
  No 57 60.0 
Injection place of administration   
  Infusion center 25 25.8 
  Hospital 17 17.5 
  Physician office 16 16.5 
Care recipient characteristic   
Age, mean (sd) 57.6  10.43 
Gender    
  Male 48 22.3 
  Female 167 77.7 
Race/Ethnicity   
  African American/Black 7 3.3 
  White/Caucasian 201 93.4 
  Other€ 13 6.1 
Type of MS   
  Relapsing–Remitting 108 50.5 
  Primary–Progressive  32 15.0 
  Secondary–Progressive  44 20.6 
  Progressive–Relapsing  13 6.1 
  Don’t know 17 7.9 
Disability status   
  No walking disability 67 31.2 
  Mild to moderate disability 74 34.4 
  Severe to total disability 74 34.4 
Medication use   
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  Yes 164 77.0 
  No 49 23.0 
Medication route of administration   
  Oral 84 51.2 
  Injection 97 59.2 
Health insurance   
  Yes 209 97.2 
  No 6 2.8 
Total 215 100.0 
SD Standard Deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, Native Hawaiian/Other 
Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with partner 
‡Other includes retired, home–maker, student, seeking work, etc.;€Other includes Asian/Indian 
Asian, Hispanic, etc.; N = 215 
 
Assessment of health utility and comparison with norms of the US adult population 
 
MS caregivers in the age group 18–44 years had significantly worse health utility scores as 
compared to their counterparts in the general adult US population (0.83 vs. 0.91, P = 0.019).  No 
significant differences between health utility scores among caregivers aged 45 years or more and 
their corresponding group in the US population were noted.  Although, male caregivers had 
significantly lower health utility scores as compared to males in the general US population (0.83 
vs. 0.88, P = 0.001), health utility scores were not found to significantly differ between female 
caregivers and their counterparts in the US population.  Figure 3.3 depicts a comparison of health 
utility scores of MS caregivers with norm values of the US population. 
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Figure 3.3 Health utility comparison of MS caregivers with US population norms 
 
Variation in health utilities across caregiver and care recipient characteristics 
Bivariate comparison of caregiver health utility scores across caregiver and care recipient 
characteristics is presented in Table 3.2.  Within their respective categories, the median health 
utility scores were lower among older (65 years and above) caregivers (p = 0.043), those with 
lower education status (less than high school) (p = 0.026), those with income less than $15,000 
(p = 0.002), and those who spent 16–20 hours/week caring for the person with MS (p = 0.002).  
In addition, health utility scores were lower among those who reported their care recipient to 
have progressive–relapsing MS (p = 0.003).  Comparison of median utility scores across care 
recipient disability status revealed a linear dose–response trend such that there was a decline in 
median health utility values with increase in care recipient disability (p < 0.001).   
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Table 3.2 Variation in caregiver health utility across caregiver and care recipient characteristics 
 Health utility 
Characteristic Mean ± SD Median (range) P value 
Caregiver characteristic    
Age   0.043 
  18–44 0.827 ± 0.207 0.844 (0.08–1.00)  
  45–64 0.846 ± 0.155 0.827 (–0.04–1.00)  
  65 and above 0.798 ± 0.173 0.816 (0.31–1.00)  
Gender   0.985 
  Male 0.828 ± 0.166   0.827 (0.08–1.00)  
  Female 0.830 ± 0.177 0.827 (–0.04–1.00)  
Race/Ethnicity   0.193 
  African American/Black 0.729 ± 0.273 0.805 (0.08–1.00)  
  White/Caucasian 0.832 ± 0.167 0.827 (–0.04–1.00)  
  Other* 0.869 ± 0.098  0.835 (0.71–1.00)  
Marital Status   0.230 
  Never Married 0.823 ± 0.131 0.827 (0.52–1.00)  
  Married 0.849 ± 0.135  0.827 (0.31–1.00)  
  †Other 0.719 ± 0.300 0.813 (–0.04–1.00)  
Education level   0.026 
  Less than high school 0.748 ± 0.035 0.768 (0.71–0.77)  
  High school or technical school 0.800 ± 0.239 0.800 (0.08–1.00)  
  College degree 0.829 ± 0.168 0.827 (–0.04–1.00)  
  Masters degree 0.872 ± 0.844 0.844 (0.44–1.00)  
  Doctoral degree 0.874 ± 0.099 0.835 (0.71–1.00)  
  Professional degree 0.878 ± 0.094 0.827 (0.77–1.00)  
Employment Status   0.001 
  Employed/self–employed full time  0.868 ± 0.138 0.844 (0.26–1.00)  
  Employed part–time 0.855 ± 0.102 0.833 (0.69–1.00)  
  Other‡ 0.783 ± 0.199 0.816 (–0.04–1.00)  
Income   0.002 
  <$15,000 0.700 ± 0.298 0.778 (–0.04–1.00)  
  $15,000–$29,999 0.776 ± 0.187 0.800 (0.31–1.00)  
  $30,000–$49,999 0.814 ± 0.140 0.827 (0.47–1.00)  
  $50,000–$100,000 0.844 ± 0.152 0.835 (0.40–1.00)  
  Over $100,000 0.888 ± 0.092 0.844 (0.71–1.00)  
  Don’t wish to answer 0.855 ± 0.167 0.835 (0.26–1.00)  
Relationship to the care recipient   0.749 
  Spouse/Significant other 0.835 ± 0.152 0.827 (0.26–1.00)  
  Parent 0.823 ± 0.158 0.838 (0.31–1.00)  
  Child 0.758 ± 0.283 0.813 (–0.04–1.00)  
  Friend/Neighbor 0.837 ± 0.224 0.827 (0.08–1.00)  
Caregiving assistance (hours/week)   0.002 
  ≤5 hours 0.891 ± 0.115 0.844 (0.52–1.00)  
  6–10 hours 0.821 ± 0.182 0.827 (0.31–1.00)  
  11–15 hours 0.852 ± 0.105 0.827 (0.60–1.00)  
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  16–20 hours 0.740 ± 0.212 0.778 (0.08–1.00)  
  ≥20 hours 0.793 ± 0.195 0.827 (–0.04–1.00)  
Living with care recipient   0.335 
  Yes  0.827 ± 0.167 0.827 (–0.04–1.00)  
  No 0.849 ± 0.200 0.927 (0.31–1.00)  
Assist with injections    0.636 
  Yes 0.804 ± 0.206 0.827 (0.08–1.00)  
  No 0.834 ± 0.174 0.833 (0.31–1.00)  
Injection place of administration   – 
  Infusion center 0.826 ± 0.221 0.844 (0.08–1.00)  
  Hospital 0.703 ± 0.308 0.827 (–0.04–1.00)  
  Physician office 0.731 ± 0.305 0.805 (–0.04–1.00)  
Care recipient characteristic    
Age   0.729 
  18–44 0.777 ± 0.255 0.827 (0.08–1.00)  
  45–64 0.837 ± 0.161 0.827 (–0.04–1.00)  
  65 and above 0.835 ± 0.146 0.827 (0.31–1.00)  
Gender    0.624 
  Male 0.835 ± 0.149 0.827 (0.40–1.00)  
  Female 0.828 ± 0.176 0.827 (–0.04–1.00)  
Race/Ethnicity   0.898 
  African American/Black 0.731 ± 0.297 0.810 (0.08–1.00)  
  White/Caucasian 0.833 ± 0.166 0.827 (–0.04–1.00)  
  Other€ 0.819 ± 0.091 0.800 (0.71–1.00)  
Type of MS   0.003 
  Relapsing–Remitting 0.842 ± 0.183 0.844 (–0.04–1.00)  
  Primary–Progressive  0.810 ± 0.152 0.822 (0.44–1.00)  
  Secondary–Progressive  0.830 ± 0.121 0.816 (0.40–1.00)  
  Progressive–Relapsing  0.700 ± 0.264 0.768 (0.08–1.00)  
  Don’t know 0.887 ± 0.088 0.844 (0.76–1.00)  
Disability status   <0.001 
  No walking disability 0.872 ± 0.160 0.844 (0.31–1.00)  
  Mild to moderate disability 0.845 ± 0.129 0.827 (0.46–1.00)  
  Severe to total disability 0.776 ± 0.200 0.810 (–0.04–1.00)  
Medication use   0.786 
  Yes 0.825 ± 0.184 0.827 (–0.04–1.00)  
  No 0.844 ± 0.115 0.827 (0.52–1.00)  
Medication route of administration   – 
  Oral 0.829 ± 0.714 0.827 (–0.04–1.00)  
  Injection 0.814 ± 0.205 0.827 (–0.04–1.00)  
Health insurance   0.540 
  Yes 0.830 ± 0.171 0.827 (–0.04–1.00)  
  No 0.809 ± 0.130 0.822 (0.60–1.00)  
SD Standard Deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, Native Hawaiian/Other 
Pacific Islander, Hispanic, etc. 
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†Other includes divorced, separated, widowed, and not married, living with partner 
‡Other includes retired, home–maker, student, seeking work, etc.;€Other includes Asian/Indian 
Asian, Hispanic, etc.; N = 215 
 
Assessment of normality and outliers 
 
Data were examined for outliers and assumption of normality prior to conducting path analysis.  
A review of D2 values revealed minimal evidence for multivariate outliers.  In addition, data 
were examined for normality by determining skewness and kurtosis (Table 3.3).  Scores on 
caregiver health utility yielded a univariate kurtosis value of 5.123 and a critical ratio of 15.333, 
thereby generating evidence for violation of assumption of normality.  Evidence for multivariate 
kurtosis was also found (multivariate kurtosis = 9.360, C.R. = 6.114).  Presence of kurtosis in the 
data is likely to severely impact tests of variance and covariance, thereby making interpretations 
based on ML estimation method difficult.  Given that reliance on estimates generated in AMOS 
v22.0 using ML estimation technique is questionable when the assumption of normality is 
violated, maximum likelihood estimator with robust standard errors (MLR) available in Mplus 
version 7.11 (Muthén & Muthén, Los Angeles, CA) (Muthén & Muthén, 2012) was used to 
conduct path analysis.  
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Table 3.3 Descriptive statistics and normality assessment of the variables in the study model 
Study variable Mean (±SD) Skewness CR Kurtosis CR Range 
Care recipient disability status (CDDS) 4.84 (±2.426) –0.157 –0.933 –1.225 –3.67 0.00–8.00 
Objective caregiver burden 3.513 (±0.634) –0.246 –1.460 1.199 3.59 1.22–5.00 
Social support 4.507 (±1.480) –0.419 –2.507 –0.675 –2.019 1.00–7.00 
Avoidance and critical coping 2.433 (±0.524) 0.012 0.074 0.236 0.707 1.00–3.94 
Problem focused and interpersonally 
supportive coping 
3.196 (±3.196) –0.575 –3.445 0.809 2.421 1.00–4.61 
Subjective caregiver burden 2.679 (±0.510) 0.284 1.701 –0.355 –1.063 1.54–4.38 
Caregiver health utility 0.830 (±0.170) –1.817 –10.875 5.123 15.333 –0.04–1.00 
CDDS Caregiver Determined Disease Steps 
CR Critical Ratio 
SD Standard Deviation 
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Table 3.4 Correlation between variables in the path model 
Variable 1 2 3 4 5 6 7 
1. Care recipient disability status (CDDS) –       
2. Objective caregiver burden 0.236** –      
3. Social support –0.078 –
0.418** 
–     
4. Avoidance and critical coping 0.061 0.396** –0.231** –    
5. Problem–focused and interpersonally 
supportive coping 
0.374** 0.063 0.198** 0.098 –   
6. Subjective caregiver burden 0.282** 0.557** –0.307** 0.512** 0.140* –  
7. Caregiver health utility –0.313** –
0.320** 
0.182** –0.153* –0.089 –0.342** – 
*Correlation is significant at 0.05 level; **Correlation is significant at 0.01 level; SD Standard Deviation 
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Bivariate correlations between variables in the study model were calculated using spearman’s 
rank correlation coefficient (Table 3.4).  Statistically significant correlations were observed 
between all variables in the path model and caregiver health utility except between problem–
focused and interpersonally supportive coping and caregiver health utility.  For example, 
moderate correlation was observed between caregiver health utility and care recipient disability 
status (r = –0.313, p < 0.01).  Moderate correlation was also found between health utility and 
caregiver objective burden (r = –0.320, p < 0.01), and between health utility and subjective 
caregiver burden (r = –0.342, p < 0.01).  A weak correlation was noted between health utility and 
caregiver perceived social support (r = 0.182, p < 0.01), and between health utility and avoidant 
and critical coping (r = –0.153, p < 0.05). 
Determinants of health utility among caregivers of individuals with MS 
 
Subjective burden was the only factor that contributed directly to caregiver health utility (–0.069, 
[95% CI: –0.119, –0.024]).  In addition to direct paths between each variable in the model and 
caregiver health utility, indirect relationships among variables and caregiver health utility were 
also examined for statistical significance using the Sobel test and bias corrected bootstrap 
confidence interval with 10,000 draws.  The relationship between care recipient disability and 
caregiver health utility was mediated by subjective burden (using the Sobel test and bias–
corrected bootstrap method [95% CI: –0.005, –0.001]).  Subjective burden was also found to 
mediate the relationship between objective burden and caregiver health utility (using the Sobel 
test and bias–corrected bootstrap method [95% CI: –0.037, –0.006]).  The relationship between 
objective burden and caregiver health utility was mediated via avoidance and critical coping and 
subjective burden (using the Sobel test and bias–corrected bootstrap method [95% CI: –0.015, –
0.002]).  The overall model fit was also evaluated for the path model.  Initial fit statistics for the 
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a priori path model included a χ2 = 28.534, df = 3; and RMSEA = 0.199 (95% CI: 0.137, 0.269).  
The initial model fit statistics indicated a poor fit for the data.  Improvements were made to the a 
priori model based on modification indices which suggested correlating the error terms for 
avoidance and critical coping and problem–focused and interpersonally supportive coping.  As 
per the revised model, fit statistics for the path model indicated marginally adequate fit for the 
data, with χ2 = 15.244, df = 2; and RMSEA = 0.175 (90% CI: 0.100, 0.262).  Due to the 
sensitivity of the χ2 likelihood test to sample size (Byrne, 2009), additional goodness of fit 
statistics were computed to ascertain model fit.  The value of comparative fit index (CFI = 0.951) 
indicated that the hypothesized model fits the data reasonably well.  The value of standardized 
root mean square residual (SRMR = 0.034) also revealed a well–fitting model.  The 
unstandardized coefficients for direct and indirect paths between caregiver health utility and 
other variables in the path model and fit indices for the model are summarized in Table 3.5. 
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Table 3.5 Unstandardized path coefficients and model fit indices for variables in the study model 
Path Estimate (SE)a 95% Confidence 
Interval (CI) 
P valueb 
Direct paths    
Objective burden → health utility –0.040 (0.022) –0.084, 0.004 0.076 
Subjective burden → health utility –0.069 (0.024) –0.119, –0.024 0.004* 
Social support → health utility 0.003 (0.008) –0.013, 0.019 0.715 
Avoidance and critical coping → health utility 0.003 (0.028) –0.055, 0.055 0.928 
Problem–focused and interpersonally supportive coping → health utility –0.025 (0.020) –0.068, 0.012 0.221 
CDDS → health utility –0.010 (0.005) –0.021, 0.001 0.059 
Indirect paths     
CDDS → subjective burden → health utility –0.002 (0.001) –0.005, 0.000 0.042* 
Objective burden → subjective burden → health utility –0.018 (0.008) –0.037, –0.006 0.017* 
Objective burden → avoidance and critical coping → subjective burden → 
health utility 
–0.007 (0.003) –0.015, –0.002 0.029* 
Model fit indices    
χ2/df 15.244/2  0.0005 
RMSEA 0.175  0.004 
CI 0.100–0.262  – 
CFI   0.951  – 
TLI 0.486  – 
SRMR 0.034  – 
aParameter estimates are obtained from bias corrected bootstrap estimates  
bFor indirect paths, P values and standard errors are obtained from Sobel test 
Covariance between residual terms of problem–focused and interpersonally supportive coping and avoidance and critical coping 
have been omitted from the table for simplicity, but were estimated in the model. 
SE Standard Error; CI Confidence Interval; RMSEA Root Mean Square Error of Approximation 
PCLOSE probability that RMSEA ≤ 0.05;  CFI Comparative Fit Index; TLI Tucker Lewis Index 
SRMR Standardized Root Mean Square Residual; CDDS Caregiver Determined Disease Steps 
*p < 0.05  
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DISCUSSION 
The current study assessed health utility among MS caregivers and the underlying factors 
predicting utilities in this population.  Health utility scores of MS caregivers were compared to 
US population norms.  Using a modified stress, coping, and appraisal model as a guiding 
framework, psychosocial predictors of health utility among MS caregivers were identified.  The 
direct and indirect relationships among factors affecting health utility were quantified using path 
analysis.  To the best of our knowledge, this is the first study in the US to evaluate health utility 
among MS caregivers using the EQ–5D–3L and identify determinants of health utility in this 
population.   
MS caregivers aged 18–44 years had significantly lower health utility scores compared to 
US population norms.  Male MS caregivers had lower health utility scores as compared to their 
counterparts in the US population; however, those among female MS caregivers did not 
significantly differ from females in the general US population.  Our results are consistent with 
those of Gupta et al. (2012), who also found lower utility scores among MS caregivers as 
compared to non–caregiver controls.  Another study conducted among caregivers of individuals 
with MS in the United Kingdom (UK) also found lower utility scores in this population as 
compared to matched controls (Acaster et al., 2013).  Norm–based health utility comparison in 
this study generated evidence for the incremental impact of caring for an individual with MS on 
the caregiver.  
 84 
 
Bivariate analyses revealed significant relationships between each predictor in the 
conceptual framework and caregiver health utility except between problem–focused and 
interpersonally supportive coping and health utility.  Care recipient disability status was found to 
be inversely related to caregiver health utility, such that greater the care recipient disability, 
lower the caregiver health utility.  Our results are consistent with previous studies that have 
reported a similar association between care recipient disability and caregiver HRQOL (Acaster et 
al., 2013; Rivera‐Navarro et al., 2009).  We found an inverse relationship between caregiver 
objective and subjective burden with utility.  Previous studies have reported a positive 
relationship between caregiver burden and HRQOL (Buhse et al., 2015).  Correlational analyses 
also showed that caregivers who perceived greater social support had higher utility.  The 
relationship between social support and HRQOL/health utility has been well–documented in the 
caregiver literature.  For example, Khanna et al. (2011) reported an association between 
perceived social support and physical and mental HRQOL among autism caregivers.  Khanna et 
al. (2013) reported a positive correlation between perceived social support and health utility 
among caregivers of individuals with autism.   
In terms of caregiver coping strategies, bivariate analyses revealed that problem–focused 
and interpersonally supportive coping was not associated with health utility; however, avoidant 
and critical coping had a negative correlation with health utility.  To explicate the relationship 
between problem–focused and interpersonally supportive coping and health utility, we examined 
the relationship between subscale scores of problem–focused and interpersonally supportive 
coping and health utility.  Among those, practical assistance coping was positively correlated 
with caregiver health utility; however, positive reframing coping and supportive engagement 
coping were not significantly related to caregiver utility.  By means of the coping inventory 
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(CMSCI) utilized in this study, caregivers were first asked to identify the main caregiving 
problem they experienced in the previous month.  Caregivers were then asked to indicate the 
strategies they often employ to deal with their main caregiving problem(s).  Given that MS is an 
unpredictable disease that presents new challenges for caregivers on a daily basis, it is likely that 
‘practical assistance’ strategies (e.g. seeking information and talking to healthcare professionals, 
purchasing assistive equipment, utilizing respite services) have a more prominent role in 
managing caregivers’ daily schedule and thus improving their health status as opposed to 
‘positive reframing’ and ‘supportive engagement’.  In addition, the insignificant relationship 
between problem–focused and interpersonally supportive coping and caregiver health utility 
could be attributed to the coping inventory (CMSCI) utilized in our study.  Considering that the 
CMSCI was developed based on coping strategies employed by Australian MS caregivers, it is 
possible that care related challenges and strategies included in the CMSCI are different as 
compared to those encountered by MS caregivers in the US.  To the best of our knowledge, ours 
is the first study to utilize CMSCI in a sample of MS caregivers in the US.  Further research is 
needed to determine relationship of CMSCI coping subscales with caregiver health outcomes and 
confirm the factor structure of CMSCI across MS caregiver samples in the US. 
The conceptual framework examined in this study demonstrated a marginally adequate fit 
with the data, indicating its usefulness in identifying predictors of health utility among MS 
caregivers.  The use of path analysis technique enabled examination of both direct and indirect 
paths among variables in the conceptual model.  An insignificant direct path between care 
recipient disability status (CDDS) and caregiver health utility was observed.  Prior studies 
examining the relationship between care recipient disability and caregiver health outcomes in 
MS have reported mixed results.  Though some including the current study have reported a lack 
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of relationship between care recipient MS disability and caregiver HRQOL (Aymerich et al., 
2009), others have found greater extent of disability among MS patients to be associated with 
lower HRQOL scores among caregivers (Acaster et al., 2013; Rivera‐Navarro et al., 2009).  The 
lack of relationship between extent of MS disability among care recipient and health utility 
among caregivers as seen in this study in contrast to prior results which demonstrated 
relationship could be attributed to multiple factors.  In the two studies that found a significant 
relationship between care recipient disability and caregiver HRQOL (Rivera‐Navarro et al., 
2009; Acaster et al., 2013), the proportion of care recipients with greater disability was higher as 
compared to our study.  In the study by Rivera‐Navarro et al. (2009), more than one–third 
(34.2%) of the care recipients were in secondary progressive phase of MS, as opposed to 20% in 
our study.  The variation in disability measures used across these studies could also potentially 
influence these differences in findings.  Rivera‐Navarro et al. (2009) assessed MS disability 
using the Kurtzke Expanded Disability Status Scale (EDSS), whereas we utilized a caregiver–
administered version of the PDDS.  Although the PDDS is strongly correlated with EDDS 
(Learmonth et al., 2013), the correlation between a caregiver–administered version of the PDDS 
(as used in this study) and EDDS has not been determined.  It should also be noted that we 
examined the relationship of care recipient MS disability with health utility, whereas previous 
studies have examined the relationship with HRQOL.  As described earlier, health utility 
examines an individual’s preference for the health condition, while HRQOL represents the 
general health status of the individual.  Though conceptually related, underlying differences in 
terms of what they represent may have contributed to the lack of relationship with care recipient 
disability to health utility in this study.  It should also be noted though that the relationship 
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between caregiver health utility and care recipient disability approached significance (p = 0.059) 
in our study, which necessitates the need for further research.  
The relationship between caregiver subjective burden and health utility was statistically 
significant.  Our results are consistent with prior studies which have found an inverse 
relationship between the two constructs (Buhse 2008; Buchanan et al., 2011; Argyriou et al., 
2011).  Caregivers who feel strained by the extent of physical and emotional toll associated with 
providing care to their loved ones with MS placed lower preference for their health state.  As 
noted earlier, caregiver subjective burden is their attitude or emotional response to taking care of 
a loved one with an illness (Montgomery, 1985).  Caregivers often feel overwhelmed due to their 
sustained role in the management of their care recipients’ lives.  Given that caregiver health 
utility is a reflection of their overall preference for a health state (Tsevat, 2000), emotional 
burden experienced by caregivers may have influenced their overall health state valuation to the 
extent that caregivers who experienced greater emotional overload as a result of their care 
responsibilities assigned a lower value to their health state.  These results suggest the importance 
of alleviating caregiver burden in order to improve the health status among MS caregivers.  
Incorporating this knowledge in caregiver support programs can avoid burnout and facilitate 
sustained involvement of caregivers in the care process of individuals with MS.   
All other direct paths between predictors in the conceptual framework and caregiver 
health utility were insignificant; however, the strength and direction of path estimates were 
consistent with the hypotheses.  The relationship between social support and caregiver health 
utility was significant in bivariate analyses; however, perceived social support was no longer a 
significant predictor of health utility in path analysis.  In their study examining correlates of MS 
caregiving process, O’Brien et al. (1995) found that perceived social support explained only a 
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small proportion of variance in caregiver health.  Similarly, perceived social support and 
caregiver health utility demonstrated a weak correlation in our study as well (r = 0.18).  Besides, 
insignificant relationship between social support and health utility could also be attributed to the 
measure (MSPSS) used to assess perceived social support in our study.  The MSPSS scale 
provides subscale scores for perceived support from three different sources including significant 
others, family, and friends.  Upon further examination of subscale scores, we found that the 
bivariate relationship between significant other subscale of MSPSS and caregiver health utility 
was insignificant.  Considering that more than three–fourth of the caregivers in our study sample 
indicated being a spouse or significant other to the care recipient with MS, perceived support 
from their significant others (loved ones with MS) may not be useful to caregivers in dealing 
with their everyday caregiving stress.  Therefore, the social support measure utilized in this study 
may not have adequately captured the concept of social support as perceived by MS caregivers.  
Although MSPSS has been previously used to assess perceived social support in other caregiver 
populations (Khanna et al., 2013; Skok et al., 2006), it has not be tested in MS caregivers.  
Support from significant others may be more relevant to caregivers of children with autism as in 
the study by Khanna and colleagues.  Future studies should consider utilizing other measures of 
social support in order to adequately capture this concept.  Also, due to the documented evidence 
regarding the detrimental influence of low perceived social support on caregiver burden (Buhse, 
2008), further studies investigating the relationship between social support and caregiver health 
status are warranted. 
Indirect paths between predictors in the model and caregiver health utility were also 
evaluated.  As previously discussed, care recipient disability status did not have a direct 
influence on caregiver health utility; however, this effect was mediated via subjective caregiver 
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burden.  We found that caregivers of individuals with greater extent of MS disability experienced 
considerable subjective burden and indicated a lower health state preference (utility).  Our results 
are consistent with a previous study that examined the factors affecting psychological well–being 
(depression) among caregivers of disabled elderly using a similar conceptual framework (Yates 
et al., 1999).  Yates and colleagues reported that caregiver objective and subjective burden 
mediated the relationship between care recipient functional disability and caregiver’s risk for 
depression such that greater extent of disability among care recipients led to caregiver overload 
and ultimately higher risk for caregiver depression.  These findings further elucidate the 
antecedents to caregiver subjective burden and point toward the relevance of this information in 
MS caregiver support programs.  It is important that clinicians take a combined patient–caregiver 
approach (as opposed to a patient–only approach) to MS treatment which focuses not only on the 
care recipient health but also on that of caregivers.   
The relationship between objective burden and caregiver health utility was mediated via 
subjective burden.  As noted before, caregiver objective burden relates to a change in tangible 
aspects of caregivers’ life including health, privacy, money, freedom, recreation, and vacation 
time as a result of caregiving responsibilities (Montgomery, 1985).  We found that caregivers 
who experienced greater objective burden encountered substantial emotional overload and 
indicated having a lower preference for their health state.  Our results are consistent with 
previous research reporting an inverse relationship between caregiver burden and HRQOL 
(Rivera–Navarro et al., 2009).  Nevertheless, a few limitations of the literature pertaining to 
caregiver burden should be taken into consideration.  Although previous researchers have 
evaluated the relationship between overall caregiver burden and caregiver HRQOL/health utility, 
most researchers have failed to distinguish between different facets of caregiver burden.  A few 
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studies that have assessed caregiver objective and subjective burden separately have reported a 
positive correlation between the two aspects of caregiver burden (Buchanan et al., 2011; Bayen 
et al., 2015; Chappell and Reid 2000; Rivera–Navarro et al., 2009; Zorowitz et al., 2011).  In 
addition, measurement of caregiver burden is not consistent across studies among MS caregivers 
(Gupta et al., 2012; Rivera–Navarro et al., 2009).  For example, Gupta and colleagues (2012) 
assessed burden among MS caregivers by simply asking them to indicate how often they felt 
caregiving was burdensome on a 5–point scale instead of using a validated measure of burden.  
Rivera–Navarro et al. (2009) assessed caregiver burden using the Zarit Caregiver Burden 
Interview which is focused only on subjective burden and ignored the objective aspect of burden.  
On the contrary, we used the Montgomery burden scale which gives objective and subjective 
caregiver burden subscale scores.  Given the deficiencies in the literature concerning the 
measurement of caregiver burden, our study made a notable contribution by demonstrating the 
relevance of both aspects of burden among MS caregivers.  Furthermore, as caregiver burden is 
amenable to intervention, health care providers and service providers can utilize this information 
and incorporate into programs to improve the health status of MS caregivers.  These strategies 
are likely to avoid caregiver withdrawal and facilitate long–term involvement of caregivers in 
management of care recipients with MS. 
Despite the significant relationship between avoidant and critical coping and health utility 
based on correlational analyses, the direct path between the two was not significant as per path 
analysis.  Yet, avoidant and critical coping was found to have an indirect influence on caregiver 
health utility via subjective caregiver burden.  It is likely that caregivers utilizing avoidant and 
critical coping strategies such as keeping problems to themselves, or pretending that the problem 
does not exist may experience greater strain and thus impaired health.  Negative behavioral 
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strategies employed by caregivers are known to adversely impact caregiver health outcomes 
including burden and HRQOL (Van Andel et al., 2011; Lovelace, 2012; Pakenham, 2002; 
Pakenham, 2005).  Caregivers should be encouraged to use more practical coping strategies and 
alerted about the negative health effects of maladaptive coping strategies in order to effectively 
deal with stressors and competing responsibilities.  Caregiver interventions should appreciate the 
potential role of situational factors (e.g. coping strategies employed by caregivers) in the process 
of adaptation among MS caregivers.   
The study has some limitations.  The cross–sectional design employed in this study 
precluded establishing causal relationships between the study variables in the conceptual 
framework.  Future studies should employ a longitudinal design to establish causality between 
study variables.  Access to MS caregiver population for the survey was obtained by partnering 
with NARCOMS (MS patient registry), where NARCOMS participants were asked to identify 
their caregivers (primary support providers).  Although to the best of our knowledge we were not 
aware of any direct way of reaching out to caregivers; however, being able to directly contact 
caregivers might have afforded us a higher response rate.  As all patients with MS in the US are 
not registered with NARCOMS, our sample may not be representative of the target population of 
interest and could limit the generalizability of our study findings.  Further, due to the web–based 
survey design that was utilized in this study to ascertain caregiver responses, the results can only 
be generalized to those with Internet access.  A non–probability sampling technique 
(convenience sampling) may also limit the generalizability of the study findings.  
Conclusion 
The study highlights a significant negative impact of caring for an individual with MS.  Health 
utilities among caregivers of individuals with MS were lower than the general US population.  
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The results from path analysis indicated that subjective caregiver burden was significantly 
associated with caregiver health utility.  Other factors including care recipient disability, 
objective caregiver burden and avoidance and critical coping indirectly affected health utility 
among MS caregivers.  Perceived social support among MS caregivers and problem focused and 
interpersonally supportive coping did not have an impact on caregiver health utility.  The study 
findings are expected to improve the present understanding of health utilities of MS caregivers.  
Theoretically driven research such as this study can be useful in designing interventions aimed at 
improving health outcomes among caregivers of individuals with MS.  These findings can be 
geared towards avoiding burnout and withdrawal among caregivers and facilitating sustained 
involvement of caregivers in the lives of those affected with MS.   
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Dear Primary support provider (caregiver), 
 
Taking care of an individual with multiple sclerosis (MS) can be a life changing experience for 
primary support providers.  The unpredictability of MS often makes it challenging for those 
caring for an individual with MS.  Researchers at University of Mississippi–School of Pharmacy 
(UM–SOP) have collaborated with the North American Research Committee on Multiple 
Sclerosis (NARCOMS) to recruit participants for this research study.  The study consists of a 
web–based survey designed to assess the burden and health state preferences of primary support 
providers (unpaid caregivers) of individuals with MS.  This research study is part of a doctoral 
(Ph.D.) research project, and has been reviewed by the Institutional Review Board (IRB) at 
University of Mississippi. 
 
The IRB has determined that this study (Protocol No. 14x–164) fulfills the human research 
subject protections obligations required by state and federal law and university policies.  If you 
have any questions, concerns, or reports regarding your rights as a participant of research, please 
contact the IRB at (662) 915–7482. 
 
Your response to this survey is extremely important for us to understand the experiences, 
preferences, and challenges faced by primary support providers (unpaid caregivers) of 
individuals with MS.  Information obtained from this study may be used in aggregated form only 
to develop interventions to alleviate the challenges of MS primary support providers (unpaid 
caregivers).  The survey should take no longer than 30 minutes to complete. We greatly 
encourage you to participate in this study. A link to the anonymous one–time survey has been 
provided below.  At the end of the survey, you will be directed to a separate website where you 
have an option to provide your email address for the sole purpose of receiving a $15 Amazon 
gift–card sent to you via email as an appreciation of your completing the survey.  We will use a 
separate website for the gift card to ensure that your email address and survey responses cannot 
be linked. 
 
http://tinyurl.com/caremsum 
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We thank you in advance for your time in providing this valuable information.   
 
Sincerely, 
 
Rahul Khanna, PhD                                                            Namita Joshi, MS 
Assistant Professor                                                             Doctoral Candidate 
Pharmacy Administration                                                   Pharmacy Administration                                                                         
University of Mississippi                                                    University of Mississippi  
School of Pharmacy                                                            School of Pharmacy  
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CAREGIVER (PRIMARY SUPPORT PROVIDER) SURVEY 
Q1 Are you above 18 years of age? 
 Yes (1) 
 No (2) 
If No Is Selected,  GO TO THANK YOU PAGE 
 
Q2 INSTRUCTIONS:  This survey should be completed by the primary caregiver (primary 
support provider [unpaid caregiver]), i.e., the individual who is most often available to assist or 
support (regardless of the level and frequency of support involved) the individual with multiple 
sclerosis (MS).  Please note that there are no right or wrong answers. This survey has five (5) 
sections. 
Section I:  
Part A– Your health and well–being 
Part B– Your caregiving experience 
Part C– Your social support 
Part D– Your coping strategies 
Section II: Disease severity of the individual with MS to whom you provide care 
Section III: About you and the individual with MS to whom you provide care 
Section IV: Your health state preference (health utility)                          
Section V: Information on your incentive for study participation 
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SECTION I: PART A – Your Health and Well–Being 
Q3   SECTION I: PART A – Your Health and Well–Being    
 
This survey asks for your views about your health.  This information will help keep track of how 
you feel and how well you are able to do your usual activities. Thank you for completing this 
survey!     
For each of the following questions, please mark an X in the one box that best describes your 
answer. 
 
In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
        1          2         3          4           5 
1. The following questions are about activities you might do during a typical day.  Does your 
health now limit you in these activities?  If so, how much? 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
    
a  Moderate activities, such as moving a table,  
  pushing a vacuum cleaner, bowling, or  
  playing golf ....................................................................       1 ..........       2 .........       3      
b  Climbing several flights of stairs .................................        1 ..........      2 ..........       3      
2. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
 All of 
the time 
Most of 
the time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
      
a  Accomplished less than you would  
like .................................................................       1 .....       2 ....       3 .....       4 ......      5    
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b  Were limited in the kind of work or  
  other activities ..............................................       1 .....       2 ....       3 .....       4 ......      5  
3. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such 
as feeling depressed or anxious)? 
 
 
All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
      
a  Accomplished less than you would  
 like ................................................................       1 .....       2 ....       3 .....       4 ......        5    
b  Did work or other activities less  
  carefully than usual ......................................      1......       2 .....        3 ....       4 .....        5  
4. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
        1          2         3           4          5 
5. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have 
been feeling.  How much of the time during the past 4 weeks... 
 All       
of the 
time 
Most    
of the 
time 
Some   
of the 
time 
A little 
of the 
time 
None   
of the 
time 
      
a. Have you felt calm and peaceful?  ..........       1 .......         2 ......        3 ......       4 .......        5    
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b. Did you have a lot of energy? ................       1 .......         2 ......        3 ......       4 .......        5     
c.  Have you felt downhearted and  
   depressed? ...............................................       1  ......         2 ......        3 ......       4 .......        5     
6. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
All of the 
time 
Most of the 
time 
Some of the  
time 
A little of the 
time 
None of the  
time 
     
        1          2         3          4           5 
 
 
 
SECTION I:  PART B – Your Caregiving Experience 
 
INSTRUCTIONS: Please indicate the extent to which your caregiving behaviors have resulted 
in a change in various aspects of your life. 
 
   A lot 
more 
(better) 
A little 
more 
(better) 
The 
same 
A little 
less 
(worse) 
A lot 
less 
(worse) 
1. Amount of time you have to 
yourself. 
1 2 3 4 5 
2. Amount of privacy you have. 1 2 3 4 5 
3. Amount of money you have 
available to meet expenses. 
1 2 3 4 5 
4. Amount of personal freedom you 
have. 
1 2 3 4 5 
5. Amount of energy you have. 1 2 3 4 5 
6. Amount of time you spend in 
recreational and/or social activities. 
1 2 3 4 5 
7. Amount of vacation activities and 
trips you take. 
1 2 3 4 5 
8. Your relationships with other family 
members. 
1 2 3 4 5 
9. Your health. 1 2 3 4 5 
 
INSTRUCTIONS: The following statements relate to attitudes and feelings that you may have 
experienced related to your caregiving experience.  Please indicate how often you have 
experienced each of these feelings. 
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Rarely/ 
never 
A little 
of the 
time 
Sometimes Often Most 
of the 
time 
1. I feel it is painful to watch the person 
that I care for to have to suffer from 
MS. 
1 2 3 4 5 
2. I feel useful in my relationship with 
the person that I care for. 
1 2 3 4 5 
3. I feel afraid for what the future holds 
for the person that I care for. 
1 2 3 4 5 
4. I feel strained in my relationship with 
the person that I care for. 
1 2 3 4 5 
5. I feel that I am contributing to the 
well–being of the person that I care 
for. 
1 2 3 4 5 
6. I feel that the person that I care for 
tries to manipulate me. 
1 2 3 4 5 
7. I feel pleased with my relationship 
with the person that I care for. 
1 2 3 4 5 
8. I feel that the person that I care for 
does not appreciate what I do for 
him/her as I would like. 
1 2 3 4 5 
9. I feel nervous and depressed about my 
relationship with the person that I care 
for. 
1 2 3 4 5 
10. I feel that the person that I care for 
makes requests which are over and 
above what s/he needs. 
1 2 3 4 5 
11. I feel that I don’t do as much for the 
person that I care for as I could or 
should. 
1 2 3 4 5 
12. I feel that the person that I care for 
seems to expect me to take care of 
him/her as if I were the only one s/he 
could depend on. 
1 2 3 4 5 
13. I feel guilty over my relationship with 
the person that I care for. 
1 2 3 4 5 
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SECTION I:  PART C – Your Social Support 
 
INSTRUCTIONS 
We are interested in how you feel about the following statements. Read each statement carefully. 
Please indicate how you feel about each statement. 
How often is someone available … 
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Very 
strongly 
disagree 
(1) 
Strongly 
disagree 
(2) 
Mildly 
disagree 
(3) 
Neutral (4) 
Mildly 
agree (5) 
Strongly 
agree (6) 
Very 
strongly 
agree (7) 
1. There is 
a special 
person who 
is around 
when I am 
in need. (1) 
              
2. There is 
a special 
person with 
whom I can 
share my 
joys and 
sorrows. (2) 
              
3. My 
family 
really tries 
to help me. 
(3) 
              
4. I get the 
emotional 
help and 
support I 
need from 
my family. 
(4) 
              
5. I have 
special 
person who 
is real 
source of 
comfort to 
me. (5) 
              
6. My 
friends 
really try to 
help me. (6) 
              
7. I can 
count on 
my friends 
when things 
go wrong. 
(7) 
              
8. I can talk 
about my 
problems 
with my 
family. (8) 
              
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9. I have 
friends with 
whom I can 
share my 
joys and 
sorrows. (9) 
              
10. There is 
a special 
person in 
my house 
who cares 
about my 
feelings. 
(10) 
              
11. My 
family is 
willing to 
help me 
make 
decisions. 
(11) 
              
12. I can 
talk about 
my 
problems 
with my 
friends. 
(12) 
              
 
 
 
 
SECTION I: PART D – Your Coping Strategies 
 
Instructions: Caring for or supporting a loved one with a chronic physical illness like Multiple 
Sclerosis (MS) can present many problems for the carer.  For example, caregiving may place 
financial burden on the carer, strain relationships, limit social activities, create emotional distress 
for the carer etc.  As well as caregiving, the carer has to deal with the fact that their loved one 
has a chronic illness.  This may also generate problems for the carer, such as grief related to the 
loved one's loss of full health.  Below please describe the main problem you have experienced in 
the last month associated with your loved one's MS and caring for or supporting him/her. 
 
 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
_____________________ 
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Rate how stressful this main problem has been for you in the past month 
 
Not at all    somewhat    extremely 
stressful     stressful     stressful 
 
    1  2         3                   4     5  6       7___ 
 
 
INSRUCTIONS: 
When we experience stress in our lives we usually try to manage it by trying out different ways 
of “coping”.  Sometimes our attempts are successful in helping us solve a problem or feel better, 
and other times they are not.  Below is a list of things that people have reported they may do 
when confronted with problems related to caring for someone with MS.  Please indicate how 
often you have tried each of the coping strategies in dealing with your main caregiving problem 
(you mentioned above) in the past month. If you were unable to identify a “main problem” 
please indicate how often you have tried each of the coping strategies in dealing with caregiving 
in general.  There are no “right” or “wrong answers.  Please substitute……. for the name of the 
person with MS whom you care for and/or support. 
 
 
 Does not 
Apply/nev
er 
Rarel
y 
Som
e 
Tim
es 
Ofte
n 
Very 
Ofte
n 
1 I talk issues through with …... in an attempt 
to solve the problems 
0 1 2 3 4 
2 I offer……. physical assistance 0 1 2 3 4 
3 I ignore the problem  or pretend it doesn’t 
exist 
0 1 2 3 4 
4 I look at the positives of the situation 0 1 2 3 4 
5 I talk to others about the problem 0 1 2 3 4 
6 I turn to work or other substitute activities 
such as gardening, hobbies or sport, to take 
my mind off the problem 
0 1 2 3 4 
7 I accept that this is how it is 0 1 2 3 4 
8 I blame myself 0 1 2 3 4 
9 I purchase assistive equipment such as 
wheelchair, incontinence aids or computer 
to assist … 
0 1 2 3 4 
10 I keep myself busy 0 1 2 3 4 
11 I try to point out the positives to ……. 0 1 2 3 4 
12 I yell or shout at…… 0 1 2 3 4 
13 I keep out of…….’s way when he/she is in 
a bad mood. 
0 1 2 3 4 
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14 I seek assistance from others, for example, 
employ people to do the housework or ask 
friends to help out. 
0 1 2 3 4 
15 I tell …… that the problem is all their fault 0 1 2 3 4 
16 I arrange my schedule so I can be with …… 
when needed 
0 1 2 3 4 
17 I wish the problem would go away 0 1 2 3 4 
18 I seek information about the problem 0 1 2 3 4 
19 I keep my problems to myself 0 1 2 3 4 
20 I utilise respite services 0 1 2 3 4 
21 I try to improve our financial situation, for 
example, work more hours, budget money 
0 1 2 3 4 
22 I try to snap …… out of it 0 1 2 3 4 
23 I take time for myself/spend time away 
from …… 
0 1 2 3 4 
24 I closely monitor …… 0 1 2 3 4 
25 I tell …… what to do 0 1 2 3 4 
26 I participate in activities we can do together 
in order to develop our relationship. 
0 1 2 3 4 
27 I criticise …… 0 1 2 3 4 
28 I try to keep aware of ……’s needs and 
endeavour to meet these, for example, I 
know when to slow down or take a rest 
0 1 2 3 4 
29 I offer emotional support to …… 0 1 2 3 4 
30 I nag …… 0 1 2 3 4 
31 I laugh and try to find humour in the 
situation 
0 1 2 3 4 
32 I talk to health care professionals about the 
problem, for example, GP, specialist or 
psychologist 
0 1 2 3 4 
33 I drink or smoke more 0 1 2 3 4 
34 I try to solve the problem on my own. 0 1 2 3 4 
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SECTION II: PART A – Care recipient disease severity (Caregiver Determined 
Disease Steps) 
 
Instructions:  Please read the choices listed below and choose the one that best describes your 
care recipient’s situation.  The care recipient is the individual with MS to whom you provide 
assistance. 
This scale focuses mainly on how well the care recipient walks. You might not find a description 
that reflects your care recipient’s condition exactly, but please mark the one category that 
describes your care recipient’s situation the best.  
 
0 Normal: The care recipient may have some mild symptoms, mostly sensory due to MS 
but these do not limit his/her activity. If the care recipient does have an attack, he/she 
returns to normal when the attack has passed. 
1 Mild Disability: The care recipient has some noticeable symptoms from his/her MS but 
they are minor and have only a small effect on his/her lifestyle. 
2 Moderate Disability: The care recipient does not have any limitations in his/her walking 
ability.  However, the care recipient does have significant problems due to MS that limit 
daily activities in other ways. 
3 Gait Disability: MS does interfere with the care recipient’s activities, especially his/her 
walking.  The care recipient can work a full day, but athletic or physically demanding 
activities are more difficult than they used to be.  The care recipient usually doesn’t need 
a cane or other assistance to walk, but he/she might need some assistance during an 
attack. 
4 Early Cane: The care recipient uses a cane or a single crutch or some other form of 
support (such as touching a wall or leaning on someone’s arm) for walking all the time or 
part of the time, especially when walking outside. I think the care recipient can walk 25 
feet in 20 seconds without a cane or crutch. The care recipient always needs some 
assistance (cane or crutch) if he/she wants to walk as far as 3 blocks. 
5 Late Cane: To be able to walk 25 feet, the care recipient has to have a cane, crutch or 
someone to hold onto.  The care recipient can get around the house or other buildings by 
holding onto furniture or touching the walls for support.  The care recipient may use a 
scooter or wheelchair if he/she wants to go greater distances. 
6 Bilateral Support: To be able to walk as far as 25 feet, the care recipient must have 2 
canes or crutches or a walker.  The care recipient may use a scooter or wheelchair for 
longer distances. 
7 Wheelchair/Scooter:  The care recipient’s main form of mobility is a wheelchair.  The 
care recipient may be able to stand and/or take one or two steps, but he/she can’t walk 25 
feet, even with crutches or a walker. 
8 Bedridden: The care recipient is unable to sit in a wheelchair for more than one hour. 
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Section III: About you and the individual with MS to whom you provide care   
INSTRUCTIONS: Please answer the following questions to help us better understand your 
responses.  Please indicate your response.   
 
Q23 Are you? 
 Male (1) 
 Female (2) 
 
Q24 What is your current age? 
 
Q25 Which of the following best describes your race or ethnicity?  
 African American/Black (1) 
 American Indian/Alaska Native (2) 
 Asian/Asian Indian (3) 
 Hispanic (4) 
 Native Hawaiian/Other Pacific Islander (5) 
 White/Caucasian (6) 
 Other (please specify) (7) ____________________ 
 
Q26 Which of the following describes your current marital status? 
 Never Married (1) 
 Married (2) 
 Divorced (3) 
 Separated (4) 
 Widowed (5) 
 Not married, living with partner (6) 
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Q27 What is the highest level of education you have completed? 
 Less than high school (1) 
 High school/GED (2) 
 Some college (3) 
 2 year college degree (4) 
 4 year college degree (5) 
 Masters' degree (6) 
 Doctoral degree (7) 
 Professional degree (8) 
 
Q28 Which of the following describes your main occupation? 
 Employed/Self–employed full time (1) 
 Employed part–time (2) 
 Retired (3) 
 Home–maker (4) 
 Student (5) 
 Seeking work (6) 
 Other (please specify) (7) ____________________ 
 
Q29 To help us understand the health care resources available to caregivers/primary support 
providers of individuals with MS, we need to ask you about your income. Please indicate 
which of the following best represents’ you family’s approximate annual income from all 
sources?  
 Less than $15,000 (1) 
 $15,000 to $29,999 (2) 
 $30,000 to $49,999 (3) 
 $50,000 to $100,000 (4) 
 Over $100,000 (5) 
 I do not wish to answer (6) 
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Q30 Does the person with MS whom you provide care currently have insurance? 
 Yes (1) 
 No (2) 
 
Answer If Does the person with MS whom you provide care currently have  insurance? Yes 
Is Selected 
Q31 What type of health insurance does s/he have? 
 
Q32 Which of the following best describes your relationship to the individual with MS to 
whom you provide care? 
 Spouse (1) 
 Parent (2) 
 Child (3) 
 Significant other (4) 
 Friend/neighbor (5) 
 Other (please specify) (6) ____________________ 
 
Q33 What is the gender of the individual with MS to whom you provide care? 
 Male (1) 
 Female (2) 
 
Q34 Please indicate the age of the individual with MS to whom you provide care? 
 
Q35 Which of the following best describes the race or ethnicity of the individual who you 
provide care for?  
 African American/Black (1) 
 American Indian/Alaska Native (2) 
 Asian/Asian Indian (3) 
 Hispanic (4) 
 Native Hawaiian/Other Pacific Islander (5) 
 White/Caucasian (6) 
 Other (please specify) (7) ____________________ 
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Q36 Which type of MS does the individual you care for have? 
 Relapsing–remitting MS (1) 
 Primary–progressive MS (2) 
 Secondary–progressive MS (3) 
 Progressive–relapsing MS (4) 
 Don't know (5) 
 
Answer If Which type of MS does the individual you care for have?  
 
Q37 Individuals with MS experience a relapse when there are new symptoms or worsening 
of old symptoms. Has the individual with MS that you care for experienced a relapse? 
 Yes (1) 
 No (2) 
 
Q38 Is the individual that you care for prescribed with medication(s) for MS? 
 Yes (1) 
 No (2) 
If No Is Selected, Then Skip To How many hours/week do you spend cari... 
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Answer If Is the individual that you care for prescribed with medication(s) for MS? Yes Is 
Selected 
Q39 Please indicate the route of administration for the medication(s) that the individual with 
MS is prescribed (check all that apply). 
 Oral (1) 
 Injection (2) 
If Injection Is Not Selected, Then Skip To How many hours/week do you spend cari... 
 
Answer If Please indicate the route of administration for the  medication(s) that the 
individual with MS is... Injection Is Selected 
Q40 Do you assist the individual with MS you care for with his/her MS treatment–related 
injections at home? 
 Yes (1) 
 No (2) 
 
Answer If Please indicate the route of administration for the medication(s) that the individual 
with MS is... Injection Is Selected 
 
Q41 Which of the following places have you taken the individual with MS you care for to 
receive his/her MS treatment–related injections (check all that apply)? 
 Infusion center (1) 
 Hospital (2) 
 Physician office (3) 
 Not applicable (4) 
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Q42 How many hours/week do you spend caring for the person with MS? 
 Less than 5 hours/week (1) 
 6–10 hours/week (2) 
 11–15 hours/week (3) 
 16–20 hours/week (4) 
 More than 20 hours/week (5) 
 
Q43 For how many years have you been providing care for the individual with MS? 
 
Q44 Do you live with the individual with MS in the same household? 
 Yes (1) 
 No (2) 
 
Q45   SECTION IV:  Your (caregiver/primary support provider) Health Utility (health state 
preferences)  
  
INSTRUCTIONS: For this section you will be redirected to a different server. Please do not 
click the "Previous" button in this section.  After completion of this section you will be 
requested to provide your email address to receive $15 Amazon gift code.    
 
INSTRUCTIONS:  
This survey asks for your views about your health.  This information will help keep track of how 
you feel and how well you are able to do your usual activities.  For each of the following 
questions, please mark an  in one box that best describes your answer. 
Mobility 
I have no problems in walking about □1 No problems 
I have some problems in walking about □2 Moderate problems 
I am confined to bed □3 Extreme problems 
Self–Care 
I have no problems with self–care □1 No problems 
I have some problems washing dressing myself □2 Moderate problems 
I am unable to wash or dress myself □3 Extreme problems 
Usual activities (e.g. work, study, housework, family, or leisure activities) 
I have no problems with performing my usual activities □1 No problems 
I have some problems performing my usual activities □2 Moderate problems 
I am unable to perform my usual activities □3 Extreme problems 
Pain/Discomfort 
I have no pain or discomfort □1 No problems 
I have moderate pain or discomfort □2 Moderate problems 
I have extreme pain or discomfort □3 Extreme problems 
Anxiety/Depression 
I am not anxious or depressed □1 No problems 
I am moderately anxious or depressed □2 Moderate problems 
I am extremely anxious or depressed □3 Extreme problems 
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To help people say how good or bad a health state is, we have drawn as scale (rather like a 
thermometer) on which the best state you can imagine is marked 100 and the worst state you can 
imagine is marked 0. 
We would like you to indicate on this scale how good or bad your own health is today, in your 
opinion.  Please do this by drawing a line from this box below to whichever point on the scale 
indicates how good or bad your health state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your health state 
today 
 
Your health state 
today 
 126 
 
 
Thank you for your time and effort in completing this survey! 
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4 CHAPTER 4 
COMPARISION OF PREFERENCE–BASED MEASURES OF HEALTH–RELATED 
QUALITY OF LIFE AMONG CAREGIVERS OF INDIVIDUALS WITH 
MULTIPLE SCLEROSIS (MS) 
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system (Grima et 
al., 2000; Mohr & Cox, 2001).  It is characterized by demyelination of nerve fibers, which leads 
to considerable neurological impairment and disability (Grima et al., 2000).  As the disease 
progresses, individuals with MS find it increasingly difficult to manage by themselves and 
require assistance from family members (caregivers) to carry out routine activities (Buhse, 
2008).  The early age of onset of MS, progressive neurological disability, and unpredictability in 
the disease course of MS offer numerous challenges for caregivers.  As a result, MS caregivers 
experience significant burden (Buhse, 2008) and impaired health–related quality of life 
(HRQOL) (Arnett, 2007; Benito‐León et al., 2003; Gupta et al., 2012).   
Generic preference–based measures of HRQOL such as the EuroQoL–five–dimensional 
questionnaire (EQ–5D–3L), the Short Form–6–dimensional questionnaire [SF–6D], and the 
Health Utility Index (HUI) have been employed to assess health state preferences among 
caregivers (Brouwer et al., 2004; Neumann et al., 1999; Wittenberg et al., 2013).  Preference–
based measures summarize positive and negative aspects of a health state into a single index 
value that ranges between 0 (death) and 1 (perfect health) (Fisk et al., 2005; Prosser et al., 2003; 
Tsevat, 2000).  Preference values obtained from these measures reflect an individual’s overall 
assessment of quality of life for a health state.  These values are utilized to calculate measurable 
outcomes in terms of quality adjusted life years (QALYs) of economic evaluations comparing 
healthcare treatments/interventions (Gold et al., 1996). 
 131 
 
The EQ–5D–3L is a standardized generic HRQOL measure that generates preference 
values.  The five health domains captured by the EQ–5D–3L include mobility, self–care, usual 
activities, pain/discomfort, and anxiety/depression, ascertained on 3 levels, where 1 = “no 
problems”, 2 = “some problems”, and 3= “extreme problems”.  The domain–level information 
can be summarized into a preference index by attaching weights to each level of the five domains 
using a scoring algorithm based on time trade–off (TTO) preference elicitation technique (Shaw 
et al., 2005).  The scoring algorithm is based on data from the US valuation study that was 
conducted to obtain the US population–based EQ–5D–3L value set by means of TTO exercises 
among a representative sample of adults in the US.  The SF–6D is another standardized 
preference–based measure which captures six health domains including physical functioning, 
role limitations, pain, vitality, social functioning, and mental health which can be summarized 
into the SF–6D preference value.  Responses on the SF–12v2 are transformed into preference–
weighted SF–6D using a scoring algorithm based on the standard gamble (SG) preference 
elicitation technique.  The scoring algorithm for the SF–6D was developed using data from the 
valuation study by means of SG exercises conducted among a representative sample of adults in 
the United Kingdom (UK) (Brazier & Roberts, 2004). 
Although the EQ–5D–3L is more commonly used to assess health state preferences 
(Richardson & Manca, 2004), other preference–based measures such as the SF–6D are also 
employed to calculate QALYs in health economic evaluations of treatments/interventions.  
Given that the EQ–5D–3L and other measures including the SF–6D and the HUI differ in terms 
of the domains covered, valuation techniques, and number of items, there may be differences in 
preference estimates obtained using these measures.  A few prior studies comparing multi–
attribute preference measures have noted a variation in estimates obtained from different 
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preference–based measures (Grieve et al., 2009).  In their study comparing HUI3 and SF–36 
preference–based SF–6D among patients undergoing a coronary intervention in a clinical trial, 
Hatoum et al. (2004) reported differences in estimates generated from the two preference–based 
measures.  Based on their study findings, they suggested against interchangeability of the HUI3 
and the SF–6D due to the potential impact on the results of health economic evaluations such as 
cost–utility analyses (CUA).  Their study results highlighted the need for additional head–to–
head comparisons between preference–based measures to define and compare relationships 
between preference estimates in different populations.  In another study, Turner et al. (2013) 
found lack of agreement between estimates obtained from the SF–6D and the EQ–5D–3L in a 
sample of depressed patients.  They recommended that SF–6D is a more suitable measure for 
health utility assessment among depressed patients.  In a study among patients with coronary 
heart disease, differences between health state preference scores obtained using the SF–6D and 
the EQ–5D–3L were reported such that there was a low level of agreement between the 
preferences obtained from the two measures (Va Stel & Buskens, 2006).  Another study 
comparing preferences generated from the EQ–5D–3L and the SF–6D across seven patient 
groups also reported differences in mean health state preference index scores obtained from the 
two measures (Brazier et al., 2004).  They suggested that the EQ–5D–3L and the SF–6D cannot 
be used interchangeably due to the differences in preference values over a range of diseases 
(Brazier et al., 2004)   
To date, only a few studies have examined health state preferences of caregivers of 
individuals with MS (Acaster et al., 2013; Gupta et al., 2012).  Gupta et al. (2012) assessed 
health state preferences of caregivers of individuals with MS using the SF–6D and found lower 
preferences among caregivers compared to a sample of individuals in the US with a mean SF–6D 
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score of 0.70.  In another study conducted among caregivers of individuals with MS in the 
United Kingdom (UK), the mean EQ–5D–3L was reported as 0.74 (Acaster et al., 2013).  
Although, the EQ–5D–3L and the SF–6D have been independently used to assess preferences of 
caregivers of individuals with MS, a direct comparison of the estimates obtained from the two 
measures among MS caregivers is non–existent.   
Given the recent attention on caregiver preferences and their inclusion in economic 
evaluations, and the dearth of literature pertaining to comparative performance of preference–
based measures in a sample of caregivers, the current study compared estimates obtained from 
two commonly used generic preference–based measures, i.e., EQ–5D–3L and SF–6D, among 
MS caregivers.  Specifically, we examined health state preferences obtained from the EQ–5D–
3L and the SF–6D, assessed the level of agreement between the two estimates, and aimed to 
identify the point of crossover between the estimates from two measures.  In addition, previous 
studies which have compared the EQ–5D–3L and SF–6D have reported SF–6D preferences to be 
higher than EQ–5D–3L preferences for individuals with less healthy health states, and EQ–5D–
3L preferences to be higher than SF–6D preferences among those in healthier states (Barton et 
al., 2008).  Therefore, we assessed if caregivers of individuals with greater MS–related 
functional disability have significantly higher scores on the SF–6D and caregivers of individuals 
with lower functional disability have significantly higher scores on the EQ–5D–3L.  Further, we 
assessed the discordance between preference estimates from the two measures and identified if 
this constituted the minimally important difference [MID].  We also aimed to determine the 
factors affecting discordance between the EQ–5D–3L and the SF–6D estimates among MS 
caregivers.   
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RESEARCH DESIGN AND METHODS 
Study design 
A cross–sectional, non–experimental design was utilized in this study.  A web–based survey was 
administered to a convenience sample of caregivers of individuals with MS.  
Study sample and data source 
The target population for this study comprised of informal caregivers of adults (≥18 years of age) 
with MS.  A convenience sample of MS caregivers was invited to participate in the study by 
seeking recruitment assistance from the North American Research Committee on Multiple 
Sclerosis (NARCOMS), which is a volunteer registry of MS patients that has a current enrolment 
of over 37,000 patients with MS.  The registry participants (individuals with MS) were requested 
to identify their caregiver or ‘the person most often available to assist or support when needed, 
regardless of the level and frequency of support involved’.  
Data collection 
A cover letter was mailed to NARCOMS registry participants (individuals with MS) requesting 
them to identify their caregiver.  Along with the cover letter, a survey invitation letter addressed 
to the caregiver was sent requesting their participation in the study.  The survey invitation letter 
informed the caregivers about the study purpose, voluntary participation in the study and 
included the link to the survey.  The survey was hosted on the Qualtrics Survey Software (Provo, 
UT), which is a web–based survey program.  The sample selection and cover letter mailing was 
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carried out by NARCOMS in order to protect the identity of participants.  As a token of 
appreciation, caregivers received a $15 Amazon gift card.  Study approval from the University of 
Mississippi’s Institutional Review Board (UM–IRB) was obtained under exempt status.    
Study measures 
This study was part of a larger study aimed at studying health state preferences among caregivers 
of individuals with MS.  The survey that was utilized in the larger parent study included several 
measures; however, only measures relevant to the objectives of the current study are reported in 
this section.   
The EuroQoL–five–dimensional questionnaire (EQ–5D–3L).  The two components of the EQ–
5D–3L include a descriptive system and a visual analogue scale (EQ–5D–3L VAS) (EuroQoL, 
1990).  Mobility, self–care, usual activities, pain/discomfort, and anxiety/depression are the five 
domains assessed by the descriptive system of the EQ–5D–3L.  There are 3 levels for each 
domain– 1 = “no problems”, 2 = “some problems”, and 3= “extreme problems”, yielding a total 
of 243 unique health states that can be defined by combining 1 level from all 5 domains.  The 
information obtained from the self–reported health states (EQ–5D–3L descriptive system) was 
converted to a single summary index using a scoring algorithm (Shaw et al., 2005).  The TTO 
preference elicitation technique forms the basis for the EQ–5D–3L.  The EQ–5D–3L VAS is 
used to record an individual’s self–reported health on a vertical 20 cm line, where end–points are 
labelled from 0 = “worst imaginable health state” to 100 = “best imaginable health state” 
(EuroQoL, 1990).  The value of EQ–5D–3L index lies between –0.59 and 1.00 based on the 
scoring algorithm.  
Medical Outcomes Study Short–Form Health Survey version 2 (SF–12v2).  Physical and mental 
health status of MS caregivers was determined using the web version of the standard SF–12v2.  
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Physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (V), 
social functioning (SF), role emotional (RE), and mental health (MH) domains were assessed 
using the SF–12v2.  Although the SF–12v2 was not originally developed to elicit health state 
preferences for calculation of QALYs, scores on SF–12v2 can be converted into short form six–
dimensional measure (SF–6D).  The SF–6D is a preference–based measure of HRQOL that 
generates health state preference values that can be employed in health economic evaluations of 
treatments/interventions (Hanmer, 2009).  There are six domains of the SF–6D: physical 
functioning, role limitation, social functioning, pain, mental health, and vitality, with 2–5 levels 
on each of the six domains, yielding about 7,500 unique health states.  The SG preference 
elicitation technique forms the basis for obtaining SF–6D health state preferences.  Responses on 
the SF–12v2 were converted into SF–6D using the SF–12v2 scoring software (Ware et al., 2002) 
which utilizes the scoring algorithm developed by Brazier and colleagues (Brazier & Roberts, 
2004).  The range of SF–6D values is between 0.345 and 1.000 (Whitehurst et al., 2011). 
Caregiver–Determined Disease Steps (CDDS).  Patient–determined disease steps (PDDS) is a 
patient–administered measure used to determine functional disability among MS patients.  The 
PDDS is measured on an 8–point scale, where 0 = “normal”, 1 = “mild disability”, 2 = 
“moderate disability”, 3 = “gait disability”, 4 = “early cane”, 5 = “bilateral support”, 6 = 
“wheelchair”, 7 = “wheelchair/scooter”, 8 = “bedridden” (Hohol et al., 1995; Hohol et al., 1999).  
The PDDS was adapted into a caregiver–administered instrument (caregiver determined disease 
steps [CDDS]) to elicit information pertaining to MS patient’s functional disability from 
caregivers of individuals with MS.  The PDDS ascertains information directly from MS patients 
about how well they walk, while the CDSS abstracts information from caregivers about how well 
care recipients with MS are able to walk.  The wording of the instructions and items was 
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modified to reflect this change.  For example, mild disability in the PDDS was described as “I 
have some noticeable symptoms…” which was changed to “the care recipient has some 
noticeable symptoms…” in the CDDS.  Approval was obtained from NARCOMS to change the 
disease steps measure from a patient–administered to a caregiver–administered instrument.  
Socio–demographic characteristics of caregivers and care recipients.  Caregivers’ age, gender, 
race/ethnicity, education status, marital status, income, employment status, co–residence with 
care–recipient, their relationship with the care–recipient, whether or not they help the care 
recipient with injections, places they have taken the care recipient for treatment–related 
injections, and weekly hours of assistance provided to care recipients were obtained.  
Information pertaining to care recipient’s age, gender, race/ethnicity, years of MS diagnosis, MS 
type, health insurance coverage, whether or not on MS prescription medications, and route of 
administration were collected.   
Data management 
The data was downloaded from Qualtrics as a Microsoft Excel file for cleaning.  Data on EQ–
5D–3L was entered in a separate excel sheet and merged with the rest of the data.  Subsequently, 
the data was imported to Statistical Package for Social Sciences version 22.0 (SPSS) Statistics 
(IBM, Corporation, Armonk, NY, US) for analyses.    
Missing data.  Responses with greater than 15% missing data were excluded from the analyses.  
For responses with fewer than 15% missing data, case mean substitution was used.  For 
responses on the EQ–5D–3L, data was complete as web–based EQ–5D–3L yields complete 
responses on all domains.  Missing data for SF–12v2 measure was substituted using the missing 
score handling technique (Missing Score Estimation [MSE]) developed by Quality Metric™ 
OptumInsight.  In order to compute the SF–6D, responses on all seven items of the SF–12v2 that 
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are used in the 6 domains of the SF–6D should be complete.  Even though missing data on SF–
12v2 is handled using the MSE, missing responses on the items used for the calculation of the 
SF–6D (n = 1 for this study) are not accounted for by the MSE.  Given the minimal missing data 
for SF–6D in this study, we excluded the one case with missing data from study analyses. 
Data analyses 
Calculation of preference scores.  Caregivers’ responses on descriptive EQ–5D–3L were 
converted to into a summary index using the scoring algorithm developed by Shaw et al. (2005).  
Similarly, caregivers’ responses on the SF–12v2 were converted to SF–6D using the SF–12v2 
scoring software (Ware et al., 2002) based on the scoring algorithm developed by Brazier and 
Roberts (2004).   
Descriptive statistics.  Means and standard deviations (SD) and frequencies and percentages 
were calculated for continuous and categorical variables, respectively.   
Examination of distribution of preference scores.  Distribution of summary health state 
preference scores on the EQ–5D–3L and SF–6D were examined by plotting Q–Q or normal 
probability plots and formal tests of normality including Kolmogorov–Smirnov and Shapiro–
Wilks tests.  Skewness and kurtosis indices were also reported. 
Analysis of agreement.  Domain–level agreement was assessed by calculating correlation 
coefficient between domains assessing similar constructs.  Spearman’s rank correlation 
coefficient was used to assess the association between relevant domains of EQ–5D–3L and SF–
6D.  The value of the correlation coefficient between 0.1 and 0.29 was considered as weak, 0.3–
0.49 as moderate and 0.5 and above was indicative of strong correlation between the two 
domains (Cohen, 1988).  Presence of moderate to strong correlation between related domains 
was considered as sufficient evidence to indicate domain–level agreement.  Relationship between 
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the following pairs of domains was tested:  EQ–5D–3L ‘mobility’ domain and SF–6D ‘physical 
functioning’ domain, EQ–5D–3L ‘anxiety/depression’ domain and SF–6D ‘mental health’ 
domain, EQ–5D–3L ‘pain/discomfort’ domain and SF–6D ‘bodily pain’ domain, EQ–5D–3L 
‘self–care’ and SF–6D ‘role emotional’ domain, EQ–5D–3L ‘self–care’ and SF–6D ‘role 
physical domain, EQ–5D–3L ‘usual activities’ domain and SF–6D ‘role emotional’ domain, EQ–
5D–3L ‘usual activities’ and SF–6D ‘role physical’ domain,  and EQ–5D–3L ‘usual activities’ 
domain and SF–6D ‘social functioning’ domain, EQ–5D–3L. 
A scatter diagram between EQ–5D–3L and SF–6D scores was plotted to identify any 
systematic trends in the data.  The point of cross over is the point above which preference 
estimates from the EQ–5D–3L is higher than scores for SF–6D, and below which estimates from 
SF–6D is predicted to be greater than those on the EQ–5D–3L (Barton et al., 2008).  To assess 
where the crossover between the EQ–5D–3L and SF–6D occurs, ordinary least square regression 
was used to estimate the relationship between EQ–5D–3L and SF–6D: SF–6D = α + β EQ–5D–
3L. 
To quantify absolute agreement between the EQ–5D–3L and SF–6D, a single measure– 
Intraclass correlation coefficient (ICC) based on a 2–way mixed effects analysis of variance 
model was calculated.  In this model, the two preference measures (EQ–5D–3L and SF–6D) 
were treated as a source of variability (Whitehurst et al., 2011).  To interpret the ICC, a value of 
0 to 0.1 was considered as “virtually none”, 0.11 to 0.40 as “slight”, 0.41 to 0.60 as “fair”, 0.61 
to 0.80 as “moderate”, and 0.81 to 1.00 as “substantial” agreement (Shrout, 1998).   
In addition, Bland–Altman plot, i.e. a plot of difference between the mean EQ–5D–3L 
and mean SF–6D scores (y–axis) and the mean of the EQ–5D–3L and SF–6D scores (x–axis) 
was constructed.  Limits of agreement for the plot were calculated as the mean difference ±1.96 
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SD of the difference.  A mean difference ~0 with ≤ 5% of the points lying outside the limits of 
agreement was considered indicative of acceptable agreement between estimates obtained from 
the EQ–5D–3L and the SF–6D measure (Bland & Altman, 1986; Bland & Altman, 1999; 
Whitehurst et al., 2011). 
To determine if caregivers of care recipients with greater MS–related functional disability 
had significantly higher scores on SF–6D and caregivers of care recipients with lower functional 
disability have significantly higher scores on the EQ–5D–3L, SF–6D and the EQ–5D–3L were 
compared across CDDS levels (0–2 = “no walking disability”, 3–5 = “mild to moderate 
disability”, and 6–8 = “severe to total disability”).  Paired t–test was used to compare the mean 
EQ–5D–3L index and the mean SF–6D score for each CDDS level.   
Discordance between EQ–5D–3L and SF–6D and identification of minimally important 
difference (MID).  Difference between EQ–5D–3L and SF–6D scores was computed.  For each 
respondent, summary EQ–5D–3L and SF–6D scores were compared using paired t–test.  A 
difference of 0.03 was considered as MID (Barton et al., 2008).  Factors affecting discordance 
were ascertained using multivariable linear regression. 
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RESULTS 
Description of the study sample 
A total of 221 responses were obtained from MS caregivers, of which 215 had completed 
responses on EQ–5D–3L and 212 had completed responses on the SF–6D.  In order to facilitate 
comparison of the two preference–based measures, 212 responses with completed data on both 
EQ–5D–3L and the SF–6D were included as the final study sample.  Table 4.1 describes the 
demographic characteristics of the caregivers and their care recipients (patients) with MS.  
Several caregivers were male (61.3%), White/Caucasian (87.7%), with a mean age of 56.7 
(±13.4) years.  A large proportion (76.9%) of caregivers were either a spouse or a significant 
other of a MS patient.  Over three–fourth of caregivers were married (78.8%) and a large 
proportion co–resided with MS patient (89.6%).  A third (33.1%) of the caregivers had an annual 
family income of $49,000 or less.  On average, caregivers were involved in providing care for 
about 16.0 (±9.7) years and 35.8% of them spent 20 hours or more per week looking after a MS 
patient.   
In terms of the characteristics of care recipients with MS, most were female (77.8%), 
White/Caucasian (93.4%), and with an average age of 57.5 (±10.4) years, respectively.  Half of 
the care recipients were reported to have relapsing–remitting MS, followed by secondary–
progressive MS (20.6%), primary–progressive MS (15.0%), and progressive–relapsing MS 
(6.1%).  More than one–third (34.4%) of the care recipients were reported having mild to 
moderate disability, while another third (34.4%) were reported to be severely or totally disabled.  
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About three–fourth (75.0%) of the care recipients were indicated as being prescribed with MS 
medication(s).   
Table 4.1 Demographic characteristics of multiple sclerosis (MS) caregivers and care recipients 
Characteristic N % 
Caregiver characteristic   
Gender   
  Male 130 61.3 
  Female 81 38.2 
Age, mean (sd) 56 13.4 
Race/Ethnicity   
  African American/Black 10 4.7 
  White/Caucasian 186 87.7 
  Other* 16 7.5 
Marital Status   
  Never Married 18 8.5 
  Married 167 78.8 
  †Other 27 12.7 
Education level   
  Less than high school 3 1.4 
  High school or technical school 28 13.2 
  College degree 127  59.9 
  Masters degree 32 15.1 
  Doctoral degree 12 5.7 
  Professional degree 9 4.2 
Employment Status   
  Employed/self–employed full time  100 47.2 
  Employed part–time 18 8.5 
  Other‡ 93 43.9 
Income   
  <$15,000 14 6.6 
  $15,000–$29,999 19 9.0 
  $30,000–$49,999 37 17.5 
  $50,000–$100,000 67 31.6 
  Over $100,000 37 17.5 
  Don’t wish to answer 38 17.9 
Relationship to the care recipient   
  Spouse/Significant other 163 76.9 
  Parent 16 7.5 
  Child 13 6.1 
  Other 18 8.5 
Caregiving assistance (hours/week)   
  ≤5 hours 65 30.7 
  6–10 hours 29 13.7 
  11–15 hours 25 11.8 
 143 
 
  16–20 hours 17 8.0 
  ≥20 hours 76 35.8 
Care years, mean (sd) 16 9.73 
Living with care recipient   
  Yes  190 89.6 
  No 22 10.4 
Assist with injections   
  Yes 37 39.0 
  No 56 61.0 
Injection place of administration   
  Infusion center 25 25.8 
  Hospital 17 17.5 
  Physician office 16 16.5 
Care recipient characteristic   
Age, mean (sd) 57.5  10.42 
Gender    
  Male 47 22.2 
  Female 165 77.8 
Race/Ethnicity   
  African American/Black 7 3.3 
  White/Caucasian 198 93.4 
  Other€ 7 3.3 
Type of MS   
  Relapsing–Remitting 106 50.0 
  Primary–Progressive  32 15.1 
  Secondary–Progressive  44 20.8 
  Progressive–Relapsing  13 6.1 
  Don’t know 16 7.5 
Disability status   
  No walking disability 66 31.1 
  Mild to moderate disability 73 34.4 
  Severe to total disability 73 34.4 
Medication use   
  Yes 161 75.9 
  No 49 23.1 
Medication route of administration   
  Oral 83 51.5 
  Injection 95 59.0 
Health insurance   
  Yes 206 97.2 
  No 6 2.8 
Total 212 100.0 
SD Standard Deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, Native Hawaiian/Other 
Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with partner. 
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‡Other includes retired, home–maker, student, seeking work, etc. 
€Other includes Asian/Indian Asian, Hispanic, etc. 
 N = 212 
 
Examination of distribution of preference scores 
The EQ–5D–3L index generated a mean preference value of 0.83 (±0.17) that ranged between –
0.040 and 1.00.  The SF–6D yielded a mean preference value of 0.74 (±0.14) and a range of 
0.345 to 1.00.  Figure 4.1 depicts histograms of the EQ–5D–3L index and SF–6D scores for the 
study sample of MS caregivers.  Discernable differences between preference score distributions 
of the two measures were noted.  The values of skewness were –1.827 and –0.163 for EQ–5D–
3L index and SF–6D, respectively.  Though both EQ–5D–3L index and SF–6D appeared to have 
a negatively skewed distribution, the SF–6D appeared to be less skewed as compared to the EQ–
5D–3L index.  The values of kurtosis were 5.22 and –0.691 for EQ–5D–3L index and SF–6D, 
respectively.   
 
Figure 4.1 Distribution of the EQ–5D–3L index and SF–6D for MS caregivers 
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Kolmogorov–Smirnov and Shapiro–Wilks tests indicated departures from normality for 
both measures.  In addition, normal probability plots for the EQ–5D–3L index and SF–6D scores 
were constructed as shown in Figure 4.2. 
  
Figure 4.2 Normal probability plots for EQ–5D–3L index and SF–6D among MS caregivers 
 
Agreement of EQ–5D–3L index and SF–6D scores 
Results of domain–level agreement between EQ–5D–3L and SF–6D scores are presented in 
Table 4.2.  Moderate association between similar domains of the two measures was observed.  
For example, a moderate correlation was noted between mobility (EQ–5D–3L) and PF (SF–6D) 
(r = –0.448).  Anxiety/depression (EQ–5D–3L) and MH (SF–6D) (r = –0.633), and 
pain/discomfort (EQ–5D–3L) and BP (SF–6D) (r = –0.590) were strongly correlated.  A weak to 
moderate correlation was reported between self–care (EQ–5D–3L) and RL (SF–6D) (r = –0.164 
[RE], –0.319 [RP]) and between usual activities (EQ–5D–3L) and RL (SF–6D) (r = –0.196 [RE], 
–0.434 [RP]).  In addition, there was a moderate correlation between usual activities (EQ–5D–
3L) and SF (SF–6D) (r = –0.330).   
Table 4.2 Correlation between the EQ–5D–3L and SF–12v2 domains 
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EQ–5D–3L 
domain 
SF–12v2 domain Correlation coefficient 
Mobility Physical functioning (PF) –0.448** 
Self–care Role limitation (Role emotional [RE], 
Role physical[RP]) 
–0.164*, –0.319** 
Usual activities Role limitation (Role emotional [RE], 
Role physical [RP]) 
–0.196*, –0.434** 
Usual activities Social functioning (SF) –0.330** 
Pain/discomfort Bodily pain (BP) –0.590** 
Anxiety/depression Mental health (MH) –0.633** 
–– Vitality (V) –– 
**p <0.01, *p <0.05 
 aValues noted represent Spearman's rank correlation coefficient 
 
Mean EQ–5D–3L index and SF–6D scores demonstrated a strong correlation (r = 0.51, p 
<0.01).  A scatter plot between EQ–5D–3L index and SF–6D (Figure 4.3) was constructed by 
regressing EQ–5D–3L index to SF–6D (β = 0.43, p <0.01) and a constant 0.38 (p <0.01) which 
further confirmed this relationship between the two scores.  The point of crossover was 
calculated based on regression analyses, where it was estimated that SF–6D = 0.38 + 0.43*EQ–
5D–3L (R2 = 0.295).  The regression equation predicted that caregivers with EQ–5D–3L < 0.668 
would score higher on the SF–6D than on the EQ–5D–3L. 
 
Figure 4.3 Scatterplot of EQ–5D–3L index and SF–6D with linear regression line and 45○ 
(perfect agreement) line 
––––––––– Reference line from equation 45◦ 
perfect agreement line 
______Regression line: SF–6D = 0.38 + 
0.43*EQ–5D–3L; R2 = 0.295 
 
 
––––––––– Reference line from equation 45◦ 
perfect agreement line 
______Regression line: SF–6D = 0.38 + 
0.43*EQ–5D–3L; R2 = 0.295 
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 An ICC of 0.46 (95% CI 0.22 to 0.61) indicated a fair level of agreement between the 
two measures, suggesting that 46% of the variation in preferences was due to between–subject 
differences.  
Figure 4.4 depicts a Bland–Altman plot of the EQ–5D–3L index and SF–6D scores for 
the study sample.  The dashed horizontal line in the Bland–Altman plot (Figure 3) represents a 
zero difference (i.e. perfect agreement) in preference estimates obtained from the EQ–5D–3L 
and SF–6D.  Positive values of the difference (points above the dashed horizontal agreement 
line) indicate that the SF–6D generates lower preference estimates than the EQ–5D–3L, and 
negative difference (points below the dashed horizontal agreement line) values indicate that the 
SF–6D generates higher preference estimates than the EQ–5D–3L.  The 95% limits of agreement 
refer to the mean preference ± 1.96 SD of the mean difference that represent the expected limits 
for 95% of the responses.  The 95% limits of agreement for the mean preference difference were 
wide (–0.207 to 0.384), suggesting a poor agreement between EQ–5D–3L index and SF–6D 
scores.   
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Figure 4.4 Bland–Altman plot for MS caregivers completing the EQ–5D–3L and the SF–6D 
 
 In order to determine if caregivers of individuals with greater MS–related functional 
disability had significantly higher scores on the SF–6D and caregivers of individuals with lower 
functional disability have significantly higher scores on the EQ–5D–3L, paired t–test was used to 
compare the mean EQ–5D–3L index and the SF–6D score across each care recipient disability 
level CDDS level (CDDS: 0–2 = “no walking disability”, 3–5 = “mild to moderate disability”, 
and 6–8 = “severe to total disability”).  Table 4.3 reports the results of comparison of EQ–5D–3L 
index and SF–6D across each disability level.  The mean caregiver EQ–5D–3L index scores 
were higher than those obtained from the SF–6D across all care recipient MS severity levels 
(CDDS). 
Table 4.3 Caregiver EQ–5D–3L Index and SF–6D scores across care recipient disability status 
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Care recipient disability level 
(CDDS) 
EQ–5D–3L Index SF–6D P value 
No walking disability 0.874 0.763 <0.001 
Mild to moderate disability 0.845 0.751 <0.001 
Severe to total disability 0.773 0.714  0.006 
CDDS caregiver determined disease steps 
0–2 = ‘No walking disability’, 3–5 = ‘Mild to moderate disability’, 6–8 = ‘Severe to total 
disability’ 
 
Discordance between EQ–5D–3L index and SF–6D 
The difference between mean EQ–5D–3L index and SF–6D preference scores (henceforth 
referred to as discordance) among MS caregivers was 0.087 (±0.15), p <0.001.  Discordance was 
greater than the commonly acceptable threshold of minimally important difference (MID = 0.03) 
between two preference–based measures (Barton et al., 2008).  Table 4.4 reports the results of 
linear regression analysis conducted to determine predictors of discordance in health state 
preference estimates from the two measures.  Caregiver marital status (β = –.129), family annual 
income (β = 0.159), and care recipient disability status (β = –.065) were significant predictors of 
discordance between preference estimates from the two measures.  The discordance in 
preference estimates was lower for caregivers who reported their marital status as other 
(divorced, separated, widowed, and not married, living with partner) compared to those who 
reported as being never married.  The discordance in caregiver preferences were higher among 
caregivers who reported annual family income between $15,000 and $29,999 versus those with 
an annual income of <$15,000.  Discordance in caregiver preferences was lower for caregivers 
taking care of an MS patient with ‘severe to total disability’ versus ‘no walking disability’.  None 
of the other predictors in the model emerged as significant in the regression analysis. 
Table 4.4 Predictors of discordance between the EQ–5D–3L and SF–6D 
Variables  B SE P value 95% CI 
Caregiver‘s characteristic   
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Age –.0004 .001 .772 –.003 .002 
Gender      
  Male –.033 .025 .200 –.083 .017 
  Female Ref. – – – – 
Race/ethnicity      
  African 
American/Black 
Ref. – – – – 
  White/Caucasian .00005 .055 .999 –.108 .109 
  Other€ .043 .065 .513 –.086 .172 
Marital Status      
  Never Married Ref. – – – – 
  Married –.060 .057 .290 –.172 .052 
  †Other –.129 .062 .040* –.251 –.006 
Education level      
  Less than high school Ref. – – – – 
  High school or 
technical school 
–.069 .118 .558 –.301 .163 
  College degree –.033 .112 .772 –.254 .189 
  Masters degree –.043 .116 .713 –.271 .186 
  Doctoral degree –.037 .120 .760 –.274 .201 
  Professional degree –.067 .123 .588 –.311 .177 
Employment Status      
  Employed/self–
employed full time  
Ref. – – – – 
  Employed part–time –.042 .045 .352 –.131 .047 
  Other‡ –.032 .029 .270 –.089 .025 
Income      
  <$15,000 Ref. – – – – 
  $15,000–$29,999 .159 .060 .009* .040 .277 
  $30,000–$49,999 .104 .061 .090 –.016 .224 
  $50,000–$100,000 .093 .056 .102 –.018 .204 
  Over $100,000 .112 .061 .066 –.008 .231 
  Don’t wish to answer .134 .084 .110 –.025 .302 
Caregiving assistance 
(hours/week) 
     
  ≤5 hours Ref. – – – – 
  6–10 hours –.007 .038 .851 –.081 .067 
  11–15 hours .059 .038 .119 –.015 .134 
  16–20 hours .006 .043 .896 –.078 .090 
  ≥20 hours .014 .030 .647 –.045 .073 
Care recipient characteristic   
Type of MS      
  Relapsing–Remitting –.049 .051 .340 –.149 .052 
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  Primary–Progressive  –.048 .057 .398 –.160 .064 
  Secondary–Progressive  –.010 .055 .854 –.118 .098 
  Progressive–Relapsing  Ref. – – – – 
  Don’t know –.037 .065 .573 –.164 .091 
Disability status      
  No walking disability Ref. – – – – 
  Mild to moderate 
disability 
–.016 .029 .580 –.072 .041 
  Severe to total 
disability 
–.065 .033 .049* –.130 .000 
Medication use      
  Yes –.018 .027 .516 –.072 .036 
  No Ref. – – – – 
‡Other includes retired, home–maker, student, seeking work, etc. 
€Other includes Asian/Indian Asian, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with partner 
CI Confidence Interval; SE Standard Error 
*p <0.05 
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DISCUSSION 
This study is the first head–to–head comparison of preference estimates from the EQ–5D–3L and 
the SF–6D in a sample of MS caregivers.  Specifically, domain– and scale–level agreement 
between the measures was evaluated.  Preference estimates from the two measures were also 
compared between caregivers of individuals with greater versus low MS–related functional 
disability.  In addition, discordance between preference estimates from the two measures was 
assessed and determined if it constituted the MID.  An exploratory analysis of factors affecting 
discordance between health state preferences obtained from the EQ–5D–3L and the SF–6D was 
also undertaken.  The results reveal significant differences between EQ–5D–3L index and SF–
6D estimates among MS caregivers.   
The mean EQ–5D–3L index score among MS caregivers was higher than their mean SF–
6D score (0.83 vs. 0.74, p <0.001).  These findings are consistent with prior literature which 
suggests that health state preferences obtained using TTO elicitation technique (EQ–5D–3L) are 
higher for individuals with milder health states and those from SG technique (SF–6D) are higher 
for individuals with more severe health states (Dolan et al., 1996).  For example, in their study 
comparing performance of the EQ–5D–3L and SF–6D among individuals aged 45 years and 
above, Barton et al. (2008) found higher EQ–5D–3L (vs. SF–6D) scores among healthier 
individuals and higher SF–6D (vs. EQ–5D–3L) scores among less healthy individuals.  Prior 
research has reported caregivers to be in a milder health state compared to diseased individuals. 
In their study examining preferences of patients with Alzheimer’s disease (AD) and their 
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caregivers, Neumann et al. (1999) found higher health utilities among caregivers for their own 
health states as compared to patients with AD.  Considering our study sample comprised of 
caregivers who have been reported to be in a milder health state, the results pertaining to higher 
EQ–5D–3L preferences (vs. SF–6D) seem to be reasonable.   
Further, we found notable differences in the distribution of the two preference–based 
measures.  Caregiver EQ–5D–3L scores appeared to be more negatively skewed with clustering 
of responses in the upper end of the preference scale.  A skewed distribution on the EQ–5D–3L 
scores reflects that a greater proportion of caregivers reported themselves in good health on the 
EQ–5D–3L, indicating a possibility of ceiling effect for the measure as reported in several prior 
studies utilizing the EQ–5D–3L (Pickard et al., 2004, Khanna et al., 2013b; Shafie et al., 2011).  
Although the SF–6D appeared to be less negatively skewed compared to the EQ–5D–3L, there 
was evidence for ceiling effect for the SF–6D scores in our study sample as well.  Findings 
pertaining to the non–normal distribution of the two measures were also reflected in the results 
of Kolmogorov–Smirnov test.  Our study results were also similar to those of Whitehurst et al. 
(2011) who conducted a systematic review comparing the EQ–5D–3L and SF–6D group mean 
scores also reported distributional differences between the two such that the EQ–5D–3L scores 
were negatively skewed while the SF–6D approximated normal distribution (Whitehurst et al., 
2011).  Similarly, Xie et al. (2007) reported a bimodal distribution for the EQ–5D–3L and 
normal distribution for the SF–6D in sample of osteoarthritis patients.  While the skewed 
distribution in the EQ–5D–3L index score is common, that on the SF–6D scores could be 
attributed to a non–diseased sample in our study where several caregivers indicated being in a 
better health state. 
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Further, we found a marked difference in the range of responses observed for the EQ–
5D–3L (–0.04 to 1.00) and SF–6D (0.345 to 1.00).  In their study comparing the EQ–5D–3L and 
the SF–6D in a sample of osteoarthritis patients in Singapore undergoing a knee surgery, the 
EQ–5D–3L index value ranged between –0.25 and 1.00; whereas, those from SF–6D were 
between 0.32 and 0.89 (Xie et al., 2007).  As suggested by Whitehurst et al. (2011), variation in 
the range of preferences obtained for the two measures can be attributed to differences in the 
lower bounds of the two measures (–0.59 for EQ–5D–3L vs. 0.29 for SF–6D) (Whitehurst et al., 
2011).  In addition, differences in the scoring range of the two preference–based measures could 
be attributed to the preference elicitation techniques (TTO for the EQ–5D–3L vs. SG for the SF–
6D) (Grieve et al., 2009). 
In terms of domain–level agreement between the two measures, we found moderate to 
strong correlation between ‘similar’ domains of the two instruments.  For example a strong 
correlation was observed between mobility (EQ–5D–3L) and PF (SF–6D), anxiety/depression 
(EQ–5D–3L) and MH (SF–6D), and pain (EQ–5D–3L) and BP (SF–6D).  Though SF (SF–6D) 
does not have a direct counterpart in the EQ–5D–3L, ‘usual activities’ is a comparable domain.  
We found a moderate correlation between SF (SF–6D) and ‘usual activities’ (EQ–5D–3L) 
domains.  Other relevant domains were found to be correlated with each other; except vitality 
domain of the SF–6D which does not have a direct counterpart in the EQ–5D–3L.  Our results 
pertaining to domain–level agreement are analogous to those of Xie et al. (2007) who also 
reported a mild to moderate agreement between estimates from the EQ–5D–3L and SF–6D in a 
sample of osteoarthritis patients undergoing a surgery.   
Although domains of the EQ–5D–3L and SF–6D were found to be related, merely 
establishing correlation between similar domains of the two measures does not indicate that the 
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measures agree with each other and that they can be interchangeably used to generate caregiver 
QALYs.  In order to assess agreement between the EQ–5D–3L and SF–6D scores of MS 
caregivers, we calculated the ICC (a measure of absolute agreement).  An ICC of 0.46 in our 
study can be interpreted as fair agreement between the two measures as per the revised ICC 
standards by Shrout et al. (1998).  In their study comparing the EQ–5D–3L and SF–6D among 
patients coronary heart disease, van Stel and Buskens (2006) reported an almost similar ICC 
value of 0.45, and suggested that there was a poor agreement between the two measures.   
We also constructed a Bland–Altman plot (Figure 4.4) to assess agreement between the 
two measures, which is considered to be more informative than a simple scatter diagram 
(Whitehurst et al., 2011).  Although a scatter plot revealed a significant association between the 
two scores, wide limits of agreement in the Bland–Altman plot exemplified poor agreement 
between the EQ–5D–3L and SF–6D scores.  Besides the differences in terms of valuation 
techniques, number of domains and levels of the EQ–5D–3L and the SF–6D, lack of agreement 
between the estimates could be due to the difference in the recall period of the two measures.  
The web–version of the EQ–5D–3L elicits responses by asking the respondents to rate their 
health state ‘today’, whereas, the SF–6D is based on the SF–12 which has a 4–week recall 
period.  Considering that our study findings indicate that the two measures do not agree with 
each other, it important to take these factors into account when selecting a measure to assess 
caregiver preferences for use in health economic evaluations. 
We also assessed if caregivers of MS patients with less functional disability have higher 
mean EQ–5D–3L scores and caregivers of MS patients with greater functional disability have 
higher mean SF–6D scores.  Based on a paired t–test comparison, we noted that mean caregiver 
EQ–5D–3L scores were higher than their mean SF–6D scores across all patient MS severity 
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levels.  On the contrary, in their study among patients with low back pain, those with poorer 
health states had higher scores on the SF–6D while EQ–5D–3L scores were higher among 
healthier patients (Søgaard et al., 2009).  Most studies comparing the EQ–5D–3L and SF–6D 
have noted such an effect in a sample of patients as opposed to patients.  Because our entire 
sample can be considered to be in a milder state as compared to a sample of patients, it justifies 
higher EQ–5D–3L values among all caregivers irrespective of the disability status of their care 
recipients.  As ours is the first study to compare estimates of preference–based measures in a 
caregiver sample, further studies are needed to validate these findings in other caregiver samples.   
We also sought to determine the crossover point between the EQ–5D–3L and SF–6D in a 
sample of MS caregivers using regression analyses.  We found that caregivers with EQ–5D–3L < 
0.668 scored higher on the SF–6D as compared to the EQ–5D–3L.  Interestingly, previous 
comparative studies of the EQ–5D–3L and SF–6D also have similar findings with respect to 
crossover point.  In their study comparing the EQ–5D–3L and SF–6D, Barton et al. (2008) found 
that patients with EQ–5D–3L index < 0.754 scored higher on the SF–6D than on the EQ–5D–3L.  
Wu et al. (2014) also found that mean EQ–5D–3L preference value was less than the mean SF–
6D for patients with EQ–5D–3L < 0.740.  The crossover point found in our study is quite similar 
to the previous studies comparing the EQ–5D–3L and SF–6D. 
Our study findings also indicate significant discordance between EQ–5D–3L index and 
the SF–6D estimates among a sample of MS caregivers (discordance  = 0.087, p <0.001).  
Previous studies comparing the two measures have also reported discordance in preference 
values.  For example, similar to the discordance found in our study, Søgaard et al. (2009) found a 
mean difference of 0.08 between EQ–5D–3L and SF–6D scores among patients with low back 
pain.  In another study, Barton et al. (2008) found MID between EQ–5D–3L and SF–6D scores 
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among individuals aged 45 years or more.  Similar to Barton et al. (2008), a discordance of 0.03 
was considered as a reference point in our study for determining if the discordance between the 
EQ–5D–3L and SF–6D constituted MID.  However, it should be noted that a difference of 0.03 
between the estimates was based on EQ–5D and SF–5D preference estimates among patients.  A 
clinically relevant difference in caregiver preference estimates may be a greater difference 
between the estimates (difference > 0.03).  Future longitudinal studies are needed to determine 
the MID for EQ–5D–3L index and SF–6D among MS caregivers. 
Caregiver marital status, annual family income, and care recipient disability status 
emerged as significant predictors of discordance in preference estimates obtained from the EQ–
5D–3L and SF–6D.  Though no prior study has explored factors affecting differences in 
preference estimates in a sample of caregivers, a few previous studies have attempted to describe 
factors associated with discordance in preference estimates among patients (Abel, 2014; Barton 
et al., 2008; Quercioli et al., 2009; Søgaard et al., 2009; Wee et al., 2007; Wu et al., 2014).  
Barton et al. (2008) found sociodemographic factors such as age, occupational status, and weight 
status to be related to differences in preference estimates obtained from EQ–5D–3L and SF–6D 
in a sample of adults (≥45 years).  Wee et al. (2007) found marital status, presence of chronic 
conditions, and family functioning measures to be associated with differences in estimates 
obtained from four different preference–based measures.  In another study, Abel (2014) assessed 
discordance between SF–6D and HUI in a sample of individuals with neurological conditions.  
Patient–related or disease–impairment factors were found to be unrelated to discordance in 
preference estimates from the two measures examined (SF–6D and HUI) (Abel, 2014).  In their 
study evaluating the interchangeability of EQ–5D–3L and SF–6D in a sample of patients with 
low back pain, Søgaard et al. (2009) found that patient characteristics did not explain the 
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discrepancies in EQ–5D–3L and SF–6D estimates.  On the other hand, Wu et al. (2014) found 
presence of acute medical conditions as a significant determinant of difference in preference 
estimates obtained from EQ–5D–3L and SF–6D among stable angina patients.  Similar to 
previous studies that have carried out an exploratory analysis to understand the factors that 
contribute to difference in preference estimates, our study indicated that sociodemographic 
factors may be of relevance when considering the interchangeability of the two instruments to 
generate MS caregiver preferences.  In addition, care recipient disability status significantly 
impacted discordance in caregiver preferences such that the discordance between estimates was 
lower among caregivers of MS patients with ‘severe to total disability’ versus ‘no walking 
disability’.  Considering the exploratory nature of this study and the increased recent attention on 
incorporating caregiver preferences in economic evaluations of healthcare 
treatments/interventions, more research examining the interchangeability of preference–based 
measures is needed.   
Our study has a few limitations.  The study sample comprised of MS caregivers of 
patients enrolled in a volunteer registry of MS patients, and may not be representative of the MS 
caregiver population in the US.  The cross–sectional design of the study did not allow us to 
evaluate responsiveness of the EQ–5D–3L and SF–6D to change and determine MID in the 
study.  In order to evaluate and compare the performance of the two measures, responsiveness of 
the two instruments to change may be an avenue for future research.  A future longitudinal study 
may be instrumental in drawing conclusions as to which preference–based measure performs 
better in terms of capturing change in caregiver preferences over time.  In addition, use of a 
web–based survey design limits the generalizability of the study findings to only those with 
Internet access.  Further, the study sample was obtained using a convenience (non–random) 
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sampling technique, which makes the study findings vulnerable to self–selection bias, thereby 
limiting the external validity of the study findings. 
Conclusion 
The results reveal significant differences in EQ–5D–3L and SF–6D preference estimates among 
MS caregivers.  Although both measures appear to assess similar domains, there was a lack of 
agreement between the EQ–5D–3L and SF–6D.  Meaningful differences between the measures 
suggest that EQ–5D–3L and SF–6D may not be used interchangeably in CUA for 
interventions/treatments specific to MS caregivers.  Discordance in health state preference 
estimates are likely to yield differential QALY estimates and subsequently impact the results of 
CUA.  Similar comparisons of alternative preference–based instruments among caregivers are 
needed to improve the current understanding of construct validity in this area.  
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5 CHAPTER 5 
SUMMARY AND FUTURE RESEARCH 
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STUDY SUMMARY 
The unpredictability in the disease course of multiple sclerosis (MS) and its symptomatic 
manifestations exert a detrimental influence on the well–being and quality of life of caregivers 
(Uccelli, 2014).  Though several studies have documented impaired health–related quality of life 
(HRQOL) among caregivers of individuals with MS (Arnett, 2007; Benito‐León et al. 2003; 
Buchanan and Huang, 2011; Gupta et al., 2012; Patti et al., 2007), health utilities among MS 
caregivers has received scant attention.  Also, much remains unknown about the factors 
associated with utilities in this population.  Moreover, with the recent increased attention on 
informal care and its incorporation in economic evaluations of therapies and interventions, it is 
important to have valid and reliable instruments for eliciting health utility values for MS 
caregivers (Stavem & Lossius, 2001).  With multiple available generic health utility instruments, 
a comparison of estimates from two different measures in a sample MS caregivers may be 
relevant.  This study addressed the aforementioned gaps in the MS caregiver literature by 
conducting a survey research study among caregivers of individuals with MS.  This study 
provides information pertaining to psychometric validation of a health utility instrument among 
MS caregivers.  In addition, health utility estimates and its determinants were identified in this 
population and the differences and similarities between utility estimates from two measures were 
also ascertained. 
Psychometric properties of the EQ–5D–3L were tested among caregivers of individuals 
with MS.  The EQ–5D–3L is a generic preference–based measure of HRQOL that has been 
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extensively employed across disease states and populations including caregivers.  Prior to its 
application to assess health status among MS caregivers, it is important that we evaluate its 
measurement properties in this population.  This is the first study to assess convergent, 
discriminant, and known–groups validity, reliability (internal consistency), and ceiling and floor 
effects for the EQ–5D–3L among MS caregivers.  The study findings indicate adequate 
convergent, discriminant, and known–groups validity, and reliability.  The instrument did not 
reveal floor effects but ceiling effects were present.  The results of this cross–sectional study 
indicate a satisfactory psychometric profile of the EQ–5D–3L among MS caregivers; however, a 
longitudinal assessment of the EQ–5D–3L in this population is needed.   
 This study addresses a pertinent gap in the MS caregiver literature by estimating health 
utilities among caregivers of individuals with MS and identifying the determinants of utilities in 
this population.  A modified model by Yates and colleagues (1999) formed the theoretical basis 
to examine predictors of health utilities among MS caregivers.  Factors including care recipient 
disability status, caregiver objective and subjective burden, social support, and coping were 
incorporated in the model that was analyzed using path analysis, a form of structural equation 
modeling (SEM) technique.  Utilities among MS caregivers were lower than the norms values 
for the general population in the United States (US).  Care recipient disability status, caregiver 
burden (objective and subjective), and avoidance and critical coping were found to significantly 
predict health utilities among MS caregivers.  Caregiver subjective burden directly influenced 
caregiver utilities while the role of care recipient disability status was mediated via caregiver 
objective burden and avoidance and critical coping.   
This study is the first head–to–head comparison of health utility estimates from EQ–5D–
3L and SF–6D among caregivers of individuals with MS.  Domain– and scale–level agreement 
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between measures was ascertained.  The discordance between utility estimates of the two 
measures was assessed and it was determined if the discordance constituted a minimally 
important difference.  In addition, an exploratory analysis was carried out to determine the 
factors associated with discordance in health utility scores.  The two measures exhibited domain–
level agreement; however, the measures did not appear to agree on a scale level.  Differences in 
utilities suggest against the interchangeably of the two measures to calculate caregiver quality 
adjusted life year (QALYs) for MS treatments/interventions.   
This dissertation study adds to the existing literature concerning the significant negative 
impact of caring for an individual with MS as reflected by caregiver burden and impaired health 
utilities.  The findings of the psychometric evaluation of the EQ–5D–3L pave the way for future 
use of the instrument to generate caregiver utilities, which may be incorporated alongside patient 
utilities into economic evaluations of MS treatments/interventions.  By assessing health utilities 
and its determinants among MS caregivers, this study provides critical information about factors 
(e.g. caregiver burden and coping strategies) which can be targeted to improve health outcomes 
among MS caregivers via interventions and support programs.  By comparing the estimates from 
two health utility measures, this study found that there are methodological differences in the 
health utility measures which should be taken into consideration when utilizing utility measures 
in health economic evaluations. 
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DIRECTIONS FOR FUTURE RESEARCH 
The findings of this dissertation study provide new avenues for future research.  This section 
describes the potential opportunities for future research for each of the three research studies that 
are part of this dissertation. 
Research study 1 
Future researchers could employ a longitudinal study design to evaluate criterion validity (e.g. 
predictive validity) of the EQ–5D–3L by determining the ability of EQ–5D–3L to predict future 
health outcomes among MS caregivers.  In addition, assessment of test–retest reliability of the 
EQ–5D–3L can also be accomplished using a longitudinal design.  Due to the ceiling effects of 
the EQ–5D–3L as observed in this study, future researchers conducting longitudinal studies 
could consider using the EuroQoL five dimensional five level questionnaire (EQ–5D–5L) to 
reduce the rate of ceiling effects. 
Research study 2 
In the conceptual model used to determine the predictors of caregiver utilities, we included only 
care recipient disability status as a stressor for MS caregivers.  Future investigators may consider 
examining the relevance of other stressors such as care recipient cognitive deficits, problems 
associated with activities of daily living (ADL) or instrumental activities of daily living (IADL), 
bladder problems, among others as caregiver stressors.  An exploratory qualitative study can be 
conducted to identify other potential stressors for MS caregivers which can be incorporated into 
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studies with larger sample sizes.  The conceptual model can be further expanded to include 
factors such as caregiver depression that are likely to play an important role in predicting utilities 
as in other caregiver populations.  Further, researchers could implement a longitudinal study 
design to test the relationships among variables in the current conceptual model utilized in this 
study.  Data collected on more than one occasion could establish causality among variables in the 
study model.  Further, the current study model could be adapted to study health utilities and its 
determinants among caregivers of individuals with other diseases as well.  Another avenue for 
future research is to explore the possibility of response shift for caregiver utilities while 
caregivers adapt to their care recipient’s disability and illness.  A longitudinal study design may 
useful in evaluating the possibility of response shift for caregiver utilities over time.   
As majority of MS caregivers in our study sample reported themselves as either a spouse 
or significant other to the individual with MS, the significant other subscale in the social support 
measure utilized in this study may be irrelevant to spousal caregivers.  Researchers could 
consider using other social support instruments that may more applicable to spousal MS 
caregivers.   
Research study 3 
We assessed discordance (difference) between utility estimates from the EQ–5D–3L and SF–6D 
and ascertained if the discordance comprises of the minimally important difference (MID).  
Future studies should consider a longitudinal design to examine MID.  Further, due to the 
exploratory nature of this study, future investigators could conduct a similar comparison in other 
MS caregiver samples to test the reliability of these findings.  Also, as ours is the first study to 
compare utility measures in a caregiver sample, more studies comparing estimates of different 
health utility instruments among caregiver populations are needed.  Though the current study 
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compared utilities obtained from commonly used generic preference–based measures i.e., the 
EQ–5D–3L and the SF–6D, future researchers could conduct a comparison with other 
preference–based measures such as the Health Utility Index (HUI) and the Quality of Well–
Being (QWB) scale among caregivers. 
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